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ENGLISH ABSTRACT 
 
Type2 diabetes is becoming epidemic all round the world, Patients with type 2 
diabetes represents over 90 percent of the diabetic population.  
A variety of reasons have been mainly traditional risk factor such as obesity 
and life style changes.  
Diabetes is a chronic illness that requires continuing medical care and patient 
self management education to prevent acute complications and to reduce the 
risk of long term complications   
The present study has been set to assess the effectiveness of the 
pharmaceutical care plan into type 2 diabetes for slowing the progressive of 
the diseases by increasing the knowledge ,awareness of patients prevent and 
identify the drug problem .  
The study was carried out at Jaber Abo Alez Clinic Center for Diabetic 
Patients. 
The cases in the study received education on the pathophysiology of diabetes 
the importance of food, eye and dental care. 
Every patient also received education on the importance of self management 
(diet control, exercise, taking medication on time and continuous clinic visit), 
particularly emphasis was given to patients with regard to the type of diet 
following the laboratory investigations. 
Blood and urine samples for the 20 cases were investigated before the study 
and after six months. 
Results were statistically analyzed. Results for HbA1c, HDL, TG and MICR 
 IV
were found to be significant (p < 0.05), were not significant FBG, TCH, and 
LDL (p > 0.05).  
Odd ratio was done between the control group and the study group after six 
months, the result was found satisfactory control for tests HDL and MICR. Not 
satisfactory control for tests Hb1c, TCH, LDL and TG.  
After three months the liver function test and  serum creatinine  were 
investigated to prevent and identify the side effects and adverse drug 
reactions, the result was found for all cases better to continue the treatment 
and that drug was found with sever side effects or harm adverse drug 
reactions either change or decreased the doses.  
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 TCARTSBA CIBARA
 
 
ﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﻬﺩﻑ ﻤﻨﻬﺎ ﺩﺭﺍﺴﺔ ﻤﺩﻯ ﺘﺄﺜﻴﺭ ﺍﻟﺭﻋﺎﻴﺔ ﺍﻟﺼﻴﺩﻻﻨﻴﺔ ﻤﺴﺘﺨﻠﺹ ﻫ 
ﻓﻲ ﺍﻟﺘﻘﻠﻴل ﺃﻭ ﺍﻟﺤﺩ ﻤﻥ ﺃﺜﺭ ﻤﺭﺽ ﺍﻟﺴﻜﺭﻱ ﻋﻠﻰ ﻤﺭﻴﺽ ﺍﻟﺴﻜﺭﻱ ﺫﻭ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ 
ﻤﻥ ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ % 58ﻤﻥ ﺨﻼل ﺯﻴﺎﺩﺓ ﺍﻟﻤﻌﺭﻓﺔ ﻭﺍﻹﺩﺭﺍﻙ ﺒﺎﻟﻨﺴﺒﺔ ﺤﻴﺙ ﻭﺠﺩ ﺃﻥ 
ﻟﺩﻭﺍﺀ ﻭﺍﻟﺘﻐﺫﻴﺔ ﺍﻟﺼﺤﻴﺔ  ﻋﻥ ﻋﻼﻗﺔ ﺍﺘﻡ ﺇﺨﺘﻴﺎﺭﻫﻡ ﻟﻠﺩﺭﺍﺴﺔ ﻟﻡ ﻴﻜﻥ ﻟﺩﻴﻬﻡ ﺃﻱ ﻤﻌﺭﻓﺔ
ﻭﺍﻟﺘﻤﺎﺭﻴﻥ ﺍﻟﺭﻴﺎﻀﻴﺔ ﻤﺜل ﺍﻟﻤﺸﻲ ﻓﻲ ﺍﻟﺘﻘﻠﻴل ﻤﻥ ﺃﻋﺭﺍﺽ ﺯﻴﺎﺩﺓ ﺍﻟﺴﻜﺭﻱ ﻭﺒﺎﻟﺘﺎﻟﻲ 
  .ﻀﺒﻁ ﻨﺴﺒﺔ ﺍﻟﺠﻠﻜﻭﺯ ﻓﻲ ﺍﻟﺩﻡ
ﻟﻘﺩ ﺘﻤﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺒﻭﻻﻴﺔ ﺍﻟﺨﺭﻁﻭﻡ ﺒﻤﺭﻜﺯ ﺠﺎﺒﺭ ﺃﺒﻭ ﺍﻟﻌﺯ ﺍﻟﺘﺨﺼﺼﻲ   
  .ﻟﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ
ﻤﺕ ﺍﻟﺤﺎﻻﺕ ﺍﻟﺘﻲ ﺘﻡ ﺇﺨﺘﻴﺎﺭﻫﺎ ﻫﻲ ﻋﺒﺎﺭﺓ ﻋﻥ ﻋﺸﺭﻴﻥ ﻤﻥ ﺍﻟﻤﺭﻀﻰ ﻭﻗﺩ ﺘ  
ﺘﻭﻋﻴﺘﻬﻡ ﺒﺯﻴﺎﺩﺓ ﺍﻹﺩﺭﺍﻙ ﻭﺯﻴﺎﺩﺓ ﻤﻌﺭﻓﺘﻬﻡ ﺒﻤﺭﺽ ﺍﻟﺴﻜﺭﻱ ﺜﻡ ﺘﻡ ﺘﺩﺭﻴﺴﻬﻡ ﺒﺎﻹﻫﺘﻤﺎﻡ 
  .ﻭﺍﻟﻌﻨﺎﻴﺔ ﺒﺎﻻﻗﺩﺍﻡ ﻭﺍﻷﻋﻴﻥ ﻭﺍﻷﺴﻨﺎﻥ ﺒﺯﻴﺎﺭﺓ ﺍﻟﻁﺒﻴﺏ ﺩﻭﺭﻴﺎﹰ ﻜل ﺴﺘﻪ ﺃﺸﻬﺭ ﺃﻭ ﺴﻨﺔ
 8ﻓﻲ ﺨﻼل ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺘﻡ ﺃﺨﺫ ﻋﻴﻨﺔ ﻤﻥ ﺍﻟﺩﻡ ﻭﺍﻟﺒﻭل ﺒﻌﺩ ﺼﻴﺎﻤﻬﻡ ﻟﻤﺩﺓ   
 ﻭﺒﻌﺩ ﺜﻼﺜﺔ ﺃﺸﻬﺭ ﺜﻡ ﺴﺘﺔ ﺃﺸﻬﺭ، ﺒﻌﺩ ﺴﺘﺔ ﺴﺎﻋﺎﺕ ﻟﻴﻼﹰ ﺜﻡ ﺘﻡ ﻓﺤﺹ ﻫﺫﻩ ﺍﻟﻌﻴﻨﺎﺕ ﻗﺒل
 :ﺃﺸﻬﺭ ﻜﺎﻨﺕ ﻨﺘﺎﺌﺠﻬﻡ ﻜﺎﻵﺘﻲ
 RCIM، GT، LDH، c1bH ﻟﻬﺫﻩ ﺍﻟﻘﻴﺎﺴﺎﺕﺍﻟﻘﻴﻤﺔ ﺍﻟﻤﻁﻠﻘﺔ  
 > p( ﻭﺠﺩﺕ   HCT، LDL ،GBF ﻟﻠﻘﻴﺎﺴﺎﺕ ﻗﻴﻤﺔ ﺍﻟﻤﻁﻠﻘﺔ  . )50.0 < p(  ﻭﺠﺩﺕ
  .)50.0
ﺃﻴﻀﺎﹰ ﻓﻲ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻗﺩ ﺘﻤﺕ ﻤﻘﺎﺭﻨﺔ ﻋﻴﻨﺎﺕ ﻫﺅﻻﺀ ﺍﻟﻤﺭﻀﻰ ﺒﻌﻴﻨﺎﺕ ﺃﺨﺫﺕ ﻤﻥ 
  .ﺤﺎﺀ ﺨﺎﻟﻴﻴﻥ ﻤﻥ ﻤﺭﺽ ﺍﻟﺴﻜﺭﻱ ﺃﻭ ﺃﻱ ﻤﺭﺽ ﺁﺨﺭﺃﺼ
  : ﻜﺎﻨﺕ ﺍﻟﻨﺘﻴﺠﺔ ﻜﺎﻵﺘﻲ ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﻌﺸﺭﻴﻥ ﻤﺭﻴﺽ  
IV 
 ﻤﻥ ﻋﻴﻨﺎﺕ ﺍﻟﻤﺭﻀﻰ ﻗﺩ ﻭﺼﻠﺕ ﺇﻟﻰ ﺍﻟﻨﺘﻴﺠﺔ ﺍﻟﻤﺭﺠﻭﺓ ﻓﻲ ﻓﺤﺹ% 001  
 ﻤﻥ ﺍﻟﻤﺭﻀﻰ ﻟﻡ ﻴﺼﻠﻭﺍ ﺇﻟﻰ ﺍﻟﻨﺘﻴﺠﺔ ﺍﻟﻤﺭﺠﻭﺓ ﻓﻲ ﻓﺤﺹ% 07 ﻭ RCIM  ﻭLDH
 ﻭ LDL  ﻭHCTﻟﻡ ﻴﺼﻠﻭﺍ ﺇﻟﻰ ﺍﻟﻨﺘﻴﺠﺔ ﺍﻟﻤﺭﺠﻭﺓ ﻓﻲ ﻓﺤﺹ % 03  ﻭc1bH
  . GTﻟﻡ ﻴﺼﻠﻭﺍ ﺇﻟﻰ ﺍﻟﻨﺘﻴﺠﺔ ﺍﻟﻤﺭﺠﻭﺓ ﻓﻲ ﻓﺤﺹ % 51
ﻭﺃﻴﻀﺎﹰ ﺇﻫﺘﻤﺕ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺒﺘﻭﻀﻴﺢ ﺃﻭ ﻤﻨﻊ ﺍﻵﺜﺎﺭ ﺍﻟﺠﺎﻨﺒﻴﺔ ﻭﺁﺜﺎﺭ ﺍﻟﺩﻭﺍﺀ   
ﺍﻷﺨﺭﻯ ﺒﻔﺤﺹ ﻨﺸﺎﻁ ﺍﻟﻜﺒﺩ ﻭﺍﻟﻜﻠﻰ ﺒﻌﺩ ﺜﻼﺜﺔ ﺃﺸﻬﺭ ﻤﻥ ﻋﻼﺝ ﺍﻟﻤﺭﻀﻰ ﻭﻜﺎﻨﺕ 
ﻨﺘﻴﺠﺔ ﻋﻴﻨﺎﺕ ﺍﻟﻤﺭﻀﻰ ﺼﺎﻟﺤﺔ ﻟﻤﺘﺎﺒﻌﺔ ﻋﻼﺠﻬﻡ ﻭﺃﻱ ﺩﻭﺍﺀ ﻭﺠﺩ ﻋﻨﺩﻩ ﺃﻱ ﺁﺜﺎﺭ 
  . ﺓ ﺘﻡ ﺘﻘﻠﻴل ﺠﺭﻋﺘﻪ ﺃﻭ ﺇﺴﺘﺒﻌﺎﺩﻩ ﻤﻥ ﻤﻌﺎﻟﺠﺔ ﺍﻟﻤﺭﻴﺽﻀﺎﺭ
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1. INTRODUCTION & LITERATURE REVIEW 
1.1 INTRODUCTION 
Diabetes mellitus is the major public health problem. Affects about 5.9% of the 
population, it is a now national epidemic, very costly disease and continuous health 
problem for the families and government. (1) 
In many developing and newly industrialized nations diabetes reached epidemic 
proportions. In 1995 it was estimated that about 118million people world wide were 
affected with type 2 diabetes. The prevalence has increased since 1958, the 
national survey data shows no sign of target of the disease and in 2010 the 
projected diabetes is expected to affect over220 million people.(1) 
The pharmacist world wide (USA, UK and Europe) is becoming directly involved 
with various members of diabetes specialists in designing health care for diabetic 
patients. This is achieved by implementation of pharmaceutical care plan which is 
responsible for evaluation of the patients drug treatment through resolving drug 
therapy problems (ensure all drug therapy that indicated is effective, safe, and 
convenient) and therapeutic goals (monitoring) to achieve therapeutic out comes.(2)  
Treatments for type 2 diabetes have expanded to include more than 20 
medications that reduce blood glucose levels in different ways. This variety of 
medications helps patients who are unable to manage their diabetes through diet 
and exercise, prone to side effects or have difficulty to adhere to their regimens.(3) 
The ability of patients with diabetes to understand and manage their 
disease in ordinary daily life is a most important prerequisite for successful therapy. 
Increase knowledge about the disease and its treatment may contribute to the 
  
2 
capacity of the patient for self care and good performance. 
The benefits of diabetes treatment are care designed to avoid, delaying the 
consequences and complications of diabetes in patients who have diseases. 
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1.2 LITERATURE REVIEW 
 
The International Pharmaceutical Federation issued in 1998 a statement on 
pharmaceutical care that” … is the responsible provision of pharmacotherapy for the 
purpose of achieving definite outcomes which improve a patient's quality of life. It is 
a collaborative process that aims to prevent or identify and solve medicinal product 
and health related problems. This is a continuous quality improvement process for 
the use of medicinal products.” (4) 
The pharmaceutical care is a health care practice with an inherent philosophy, 
responsible for the management of the patient's therapy and care. (4) 
The responsibility of pharmacist becoming direct into individual patients to work with 
other professionals to improve the quality of life of the patients and in designing 
health care plan in cure of a disease, elimination or  reduction of a patient’s 
symptoms, slowing of a disease process, or preventing a disease.  
The pharmacist can be placed in the community and hospitals to educate the 
diabetic patients to be aware about hypoglycemia and hyperglycemia, evaluate 
patients knowledge about diabetic disease, the sign and symptoms of diabetes, to 
advise the patients on ways to improve glucose control, recommended appropriate 
OTC or non-drug management, the importance of clinical attendance and 
importance of foot, eye and dental care. 
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1.2.1 The prevalence of diabetes: 
The prevalence of diabetes for all age-groups world wide was estimated to be 2.8% 
in 2000 and 4.4%in 2030.The urban population in developing countries is projected 
to double between2000 and 2030. The most demographic change to diabetes 
prevalence across the world appears to be increase in the proportions of people>65 
years age. (5) 
Recent reports describe type2 diabetes being diagnosed in children and 
adolescents, (5) this is likely to increase further the burden of chronic diabetic 
complications world wide such as kidney failure blindness and lower extremity 
amputation. 
In Africa diabetes prevalence rises over the past 20 years due to lifestyle 
changes. The prevalence of diabetes in African communities is increasing with 
aging of the population and lifestyle changes associated with rapid urbanizations. (6) 
Traditional rural communities still have very low prevalence, at most 1-2% except in 
some specific high risk groups, while 1-13% or more adults in urban communities 
have diabetes. (6) Type 2 diabetes is predominant from 70-90%. Due to the high 
urban growth rate, dietary changes, reduction in physical activity, and increasing 
obesity, its estimated that the prevalence of diabetes will be tripled in the next 25 
years .The combinations of the rising prevalence of diabetes and a high rate of long 
term complications in Africa will lead to a drastic increase of the burden of diabetes 
on health care system of African countries.  
Diabetes Mellitus in Sudan, as in many developing countries, constitutes a 
growing health problem with a major impact on the countries econamy. It can be 
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estimated from hospital records that the number of diabetic patients is increasing in 
all socioeconomics classes. Non Insulin Dependent diabetes mellitus accounted for 
75% of all diabetic patients attending out- patient diabetes clinic in Khartoum State. 
39-49% Obesity was feature characterizing all the diabetic patients, and with a 
strong association with family history of diabetes. 
In previous studies found that in Sudan, NIDDM is a common disease with severe 
clinical course, and most patients are poorly controlled and exhibit a high 
prevalence of acute and chronic complications. The prevalence of macro and 
microvascular complications was more common among the older patients and in 
patients with poor metabolic control. Chronic renal failure was present in almost 
one- third of the patients with nephropathy. (6) A group of NIDDM patients showed a 
higher prevalence of hypertensions 44% than non diabetic subjects. 
The poor metabolic control of Sudanese diabetic patients was attributed to poor 
compliance, poor knowledge of diabetes on the part of the patients, and to the 
problem associated with injections and drug availability. (5) 
In Sudan, the prevalence of type 2 diabetes is 3.4% among adult, most of the 
patients received little or no education about how to care and control the dieses and 
there for the patients suffering from acute and chronic diabetic complications. (5) 
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1.2.2 Definition of diabetes:  
The WHO, defines diabetes mellitus as” a metabolic disorder of multiple a etiology 
characterised by chronic hyperglycemia with disturbances of carbohydrate, fat and 
protein metabolism resulting from defects in insulin secretion or in both. (7) 
Diabetes mellitus is a chronic illness characterised by raised blood glucose level 
due to a relative or absolute lack of insulin; therefore, all diabetic patients have been 
shown to develop microvascular and or macrovascular complications such as 
retinopathy, nephropathy, neuropathy lead to pain or loss of lower limb amputations, 
Foot ulcers and cardio vascular disease. 
1.2.3 Classifications of diabetes:- 
There are four types of diabetes: 
1- Type1 (insulin dependent diabetes mellitus) characterised by insulin deficiency 
due to destruction of the β cell of the pancreas therefore the patient need 
exogenous insulin to survive or is going to develop diabetic kitoacidosis.   
2-Type2 (non insulin dependent diabetes mellitus) the cause is resistance of 
insulin action into cell  but the patient will not need exogenous insulin like 
type1 because there is  sufficient amount of insulin which prevent  
kitoacidosis, in the late stages there is need for insulin when the  patient is  
not controlled by oral treatment.  
3- Diabetes due to genetic disease of pancreas or insulin action, diabetes may be 
induced by drugs, chemicals and also malnutrition may lead to diabetes. 
4- Gestational diabetes that occurs during pregnancy. 
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1.2.4 Type 2 diabetes mellitus:- 
Type 2 diabetes mellitus affects approximately 90% of the diabetic population, 
characterized by resistance to insulin actions. Diabetes results from interaction 
between genetic and environmental factor. A variety of disorders have been 
observed in type2 diabetes, these disorders include obesity, atherosclerosis, 
hyperlipidemia, and hypertension. The relationship between the disorder and type 2 
defined as syndrome x, insulin resistance syndrome was described first by Dr. 
Gerald Reaven. (11) 
Patients with type 2 diabetes exhibit varying degrees of tissue resistance to insulin, 
impaired insulin secretion, and increased basal hepatic productions of gluocose.  
The onset of type 2 diabetes is gradual, and symptoms are generally are mild 
because these patients have sufficient insulin concentrations to prevent lipolysis, 
there is usually no history of ketoacidosis except in situations of stress (e.g., 
infections or trauma).  
Type 2 diabetes is serious and common disease, manageble if patients go to the 
right way of the treatment guideline and self management, it occurs in people over 
40 years of age, over weight and family history of diabetes and more common in 
members of certain racial/ethnic groups, in women with prior gestational diabetes 
mellitus and the risk of developing type 2 diabetes increase with age, obesity and 
lack of physical activity.  
The sub classification of type 2 diabetes is based on weight. 
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1.2.4.1 Classification of type 2 diabetes:- 
1.Nonobese when BMI between23-29kg/m2.This group comprise approximately 
10% of type 2 diabetic population and associated strongly with family history of 
diabetes, their insulin levels are low in response to a glucose challenge.  They 
develop diabetes usually at age<25 years. (11)   
2. Obese BMI>30 kg/ m2.Constitute the majority of diabetic population (60% 
to90% of the type 2 diabetic population). 
 
  
9 
 
NIDDM 
↓ 
Obesity (excessive food intake) +inherited genetic defect 
↓ 
Insulin resistance 
↓ 
Hyperinsulinemia 
↓ 
Decreased number of insulin receptors 
↓ 
Prolonged postprandial hyperglycemia 
↓ 
Loss of ß-cell sensetivity to glucose 
↓ 
Loss of -cell sensetivity to glucose 
↓ 
+ Loss of insulin response to glucose and hyperglucagonemia 
↓ 
Fasting hyperglycemia 
↓ 
↓            ↓ 
Progressive loss of B-cell responsiveness                                  Gluucosuria 
↓                                                                                       ↓ 
Hypoinsulinemia                                                           Weight loss 
 
Fig. (1): Schematic representation of the pathogenesis of type 2 DM 
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1.2.4.2 Diagnosis of type 2 diabetes:- 
Various groups including the WHO and National Diabetes Data Group, have 
established criteria for the diagnosis of diabetes  based  upon the Oral Glucose  
Tolerance Test OGTT .The criteria developed by National Diabetes Data Group 
have been modified by the American Diabetes Association (ADA). For non pregnant 
individuals of any age, a diagnosis of diabetes can be made if at least one of the 
following is present: 
? The patient presents with classical signs and symptoms of diabetes (polyuria, 
polydipsia, rapid weight loss) and have a plasma glucose concentration of 
fasting>126 mg/dl on two or more occasions or random venous plasma 
glucose concentration>200mg/dl. 
? OGTT 75 gm glucose for an adult if the venous plasma glucose 
concentration is greater than or equal to 200mg/dl at two hours and greater 
than 200mg/dl at least on other time is between (0.5,1,1.5hr). 
For the OGTT, the subject is tested in the morning, after overnight fast. After taking 
a fasting blood sample, 75g of glucose is given by mouth, often in the form of a 
glucose drink such as Lactose. 
Diabetes can also diagnosed in those with symptoms and markedly raised blood 
glucose concentration.  
IGT and IFG are risk factors for diabetes and cardiovascular disease and are 
associated with insulin resistance syndrome (insulin resistantce, hyperinsulinemia, 
dyslipidemia, and hypertension). (11) 
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Table (1): Normal and Diabetic Plasma Glucose level in mg/dl (m Mol) for the 
Oral Glucose Tolerance Test Table1. 
 
Fasting                      .5, 1hr                   1.5 hr                      2 hr 
Normal                    <110 (6.5)            <200 (11)                  <140 (7.8) 
Impair                     <140 (7.8)            >200(11)                  140-200(7.8-11) 
Glucose   
Tolerance Test 
Diabetes Non-        >140 (7.8)           >200 (11)                   >200 (11) 
pregnant adult 
1.2.4.3 Treatment of type2 diabetes: 
The primary goal of type 2 diabetes treatment and management is to lower fasting 
blood glucose levels to under the range of 125mg/dl-140 mg/dl, postprandial plasma 
glucose level under the rang of 140mg/dl-199mg/dl and glycated hemoglobin at the 
rang < 7 % to prevent the occurrence of macrovascular and microvascular 
complications which has the greatest impact on the morbidity and mortality of 
patients with diabetes. (8) 
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Table (2): Goals of therapy. (8) 
Parameter normal acceptable fair poor 
Fasting plasma Glucose mg/dl <110 <140 <200 >200
Postprandial plasma Glucose mg/dl <140 <175 <235 >235
Glycosated  
Hemoglobin (%) 
<6 <8 8-9.5 >10 
        Increase limits 10% for the elderly patients 
The secondary goals are; in addition to metabolic control maintain the normal body 
mass index, blood pressure and lipid profiles into normal levels to reach a healthy 
life far from diabetes complications. 
Reducing morbidity and mortality and improving quality of life for people with 
diabetes is a major public health objective. 
As part of the health policy in 2010 initiative, goals have been set to prevent 
diabetes, early diagnosis, improve means of screening for complications, and 
decrease morbidity and mortality. (8) 
There is increasing evidence that, if there is effective interventions; including 
changes in dietary habits with increased physical activity and intensive 
pharmacological treatment reduce the prevalence of diabetic's complications. (5) 
The cornerstone in type 2 diabetes treatment is beginning by: 
1- Non pharmacological treatment: 
Life style modifications for patients with type 2 diabetes are; the food 
composition, weight loss and physical activity for obese and overweight. These 
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measures will decrease insulin resistance. 
In a randomized clinical trial involving 3234 overweight men and women aged 25-
85 years with impaired glucose tolerance, intervention with low fat diet and 150 
minutes of moderate exercise per week reduced the risk of progression to type 
2diabetes by 58% as compared to matched control group. (9) 
1.1Diet control: 
At least two-thirds of people with type 2 diabetes are over- weight. (9)  An excess of 
calories, high-fat diet, yields positive energy balance and then these people will 
develop obesity and type 2 diabetes. 
A prospective 12-year study of 4,970 overweight people with type2 diabetes 
intentional weight loss was associated with a 25% reduction in total mortality(9); 
these studies show that vigorous management of diabetes are both efficacious and 
cost effective. 
The average amount of carbohydrate recommended by The American Diabetes 
Association for patients with diabetes is 55% to 60% of the total caloric intake. 
Carbohydrates are widely distributed in the body which can synthesize from plants 
source when taken with meals or from glycerol and amino acids in human body.  
Starches which are complex of carbohydrates, when metabolized in the body will 
convert into 100% of glucose.  
Different type of starches have different  glycemic index, so the patients is advice to 
have different type of carbohydrates in a day because starch from wheat like white 
bread has different glycemic index when compare with rice, cereals , potatoes, 
cassava and others grains. (26)  
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Also the structure and texture of the carbohydrates affect the glycemic index. Whole 
grains and high fiber foods act to slow down glucose absorption so starches mixed 
with food containing fiber slow down glucose absorption. 
Vegetable and fruits also give small glycemic index when compared with 
carbohydrates. Eat two to three portions a day from vegetable and fruits in different 
time. (26) 
Low glycemic index meals allow the body to slow down the absorption of the 
carbohydrates and help the patient to avoid hypoglycemia. 
Normal fat intake recommended by The American Diabetes Association for patients 
with diabetes is 30% of total caloric intake. (12) 
Low fat foods enhance body to lose weight, because fatty foods have a high calorie 
content that increases weight gain.  
Saturated fat (fatty meat, full fat dairy products like butter) should be replaced by 
monounsaturated fats (rapeseed oil and polyunsaturated fats (sunflower, corn oil 
and Soya oil also found in oily sea foods such as sardines) also transunsaturated 
fats that are formed from the hardening of vegetable oil. (26) 
Intake of proteins should be 10% to20% as recommended by The American 
Diabetes Association for patients with diabetes. (12) 
Restriction of salt intake for hypertensive diabetic patients. (12) 
1.2 Physical activity 
Physical activity improves blood glucose levels in diabetic patients, as a result of 
increasing insulin sensitivity. 
The American Diabetes Association recommends the duration of exercise 
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(e.g. walking) to be not less than 20 minutes every 48 hours for diabetics. (12) 
The benefits of long term physical activity programs for diabetic patients with type 2 
are; treatment and prevention of metabolic abnormalities related to 
hyperinsulinemia such as; hypertension, hyperlipidemia and cardiovascular disease. 
(10) 
1.3 Cessations of smoking and alcohol. 
Importance of stopping smoking and alcohol as patients can. (12) 
1.4 Advising patients on the importance of clinical attendance. (12) 
1.5 Importance of foot, eye and dental care. (12) 
2- Pharmacological treatment: 
2.1 Oral Hypoglycemics:- 
Four groups are registered in Sudan register are:  Sulphonylures, Biguanides, 
Acarbose and Thiazolidinediones. 
 Another group the repaglinide, come from foreign private centers and also in use 
but not registered.
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Fig. (2): Shows the outlines the sites of action of the oral hypoglycemic agents 
commonly used in the treatment of type 2 diabetes. 
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Sulphonylures: 
The sulphaonylureas act mainly by augmenting insulin secretion and effective only 
when there is some residual pancreatic beta cell activity.  
During long term administration they also have an extrapancretic action, like 
reducing the rate of hepatic glucose production, increasing insulin sensitivity and 
receptors numbering, and potentiation insulin effects.  
All may cause hypoglycemia which indicates excessive dosage but this not 
common. 
Several sulphonylureas are available and choice is determined by side effects and 
the duration of action as well as the patients' age and renal function. 
Caution is needed in the elderly and in those with mild to moderate hepatic and 
renal impairment because of the hazard of hypoglycemia. 
Sulfonylureas are classified into two groups or generations based on their potency, 
duration of action and drug interaction, side effect profile and exert their effect by 
increasing B-cell insulin secretion. 
The first generation sulfonylureas include tolbutamide, chlorprobamide, tolazamide 
and acetohexmide. 
Three second generation of sulfonylurea are glibenclamide, glicalazide and 
glimepride, these agents are mainly used in Sudan.  
These agents are at least 100 times more potent on weight basis than first 
generation drugs and have duration of action up to 24 hours. Their effect on FPG 
and Hb1c are similar to the first generation sulfonylureas and has fewer side effects.  
The long acting sulphaonylureas chlorpropamide and glibenclamide are associated 
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with a greater risk of hypoglycemia; for this reason they should be avoided in the 
elderly and shorter acting can be used instead eg glicalazide or tolbutamide. 
Glicalazide is an intermediate-acting second generation agent with half life of two to 
four hours, but a duration of action of 10 to 24 hours, whereas glimepirides duration 
of action in 18-24 hours and can be given once daily . The absorption is impaired by 
the meals; it should be administered 30 min before meals. The drug is hydroxylated 
in the liver to its active compounds that are renaly excreted. Once daily dosing can 
be achieved with doses of 15 mg or less, larger doses should be divided and 
administered twice a day. 
Glyburide was approved by the FDA as twice as potent as glicalazide on weight 
basis, there fore the maximum daily dose of Glyburide is 20 mg and that of 
glicalazide is 40 mg. More recent studies have shown that adequate glycemic 
control can be produced by equal doses (11). 
Biguanides: 
The biguanides are described more accurately as antihyperglycemia agents. 
Although they lower blood glucose concentrations in diabetics, they do not cause 
hypoglycemia in non diabetic individuals.  Unlike the oral sulfonylureas, they don’t 
stimulate the release of insulin from the pancreas. They may decrease or slow the 
GIT absorption of the carbohydrates, increase peripheral utilization of glucose, 
enhance insulin binding to its receptors, or decrease glucose output.  
Other beneficial effects of metformin include; improved lipid profile by increase HDL, 
decrease LDL, decreased TG and modest weight loss with no weight gain.(11)  
Metformin the only one available biguanides, has a different mode of 
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action , It exerts its effect mainly by decreasing gluconeogenesis and by increasing 
peripheral utilization of glucose, it acts only in the presence of endogenous insulin it 
is effective only in diabetics with residual functioning pancreatic islet cells. 
Metformin is the drug of choice in obese patients in whom strict dieting has failed to 
control the blood sugar. 
The starting dose is 500mg with or after food and can increase gradually after week 
to 500 mg tds or 850 mg bd. 
Metformin contraindicated in: 
• Patients with renal impairment. 
• Elderly people above the age of 70 years. 
• Patients with heart failure, hepatic impairment, or predisposition to lactic 
acidosis. 
Treatment with Metformin should be discontinued during surgery, sever infections 
and intercurrent illnesses. 
Metformin can be combined with Sulphonylureas when therapeutic targets are not 
achieved by only one drug theraby and it has been reported that combined therapy 
of Metformin and Sulfonylureas lower basal glucose concentrations 
approximately20% more than with Sulfonylureas alone. (7,11) 
Acarbose 
The α-glucoosdase family or enzymes, which include glucoamylase, sucrase, 
maltase, isomaltase and lactase, hydrolyze complex starches into oligo 
monosaccharides and glucose, which are readily absorbed. 
Acarbose inhibits the action of intestinal amylase and α- glucosidase action and 
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causes a delay in the breakdown of complex carbohydrates into glucose. 
This results in reduced peak effect of postprandial plasma glucose.  
The main side effect is high incidence of flatulence.  
This type of drug can be used in combination with insulin, sulfonylurea and 
Metformin (10,11). 
Thiazolidinediones 
Are new classes of drug that reduce insulin resistance. Initially the use was limited 
to type 2 patients using insulin HbA1c >8.5% but was later expanded to include 
monotherapy or use combined with a sulfonylurea. These agents reduce insulin 
resistance in peripheral tissue by their effects on enzyme systems and they require 
several weeks to determine their clinical effect in a patient. Thiazolidinediones 
enhance insulin action in muscle, liver, and fat tissue. They also reduce hepatic 
glucose output and have lipid-lowering and mild antihypertensive effects.  
This type of the drug needs  routine monitoring of liver function test and should be 
discontinue  when the liver function tests rise(SGPT) to three times the normal level. 
(10,11) 
Repaglinide is anovel enaantimomeric benzoic acid derivative. It promotes the 
secretion of insulin by closing ATP-sensitive potassium channels in the ß-cell 
membrane. Although sulphonylures stimulate the same secretory mechanism, 
studies in vitro indicate that repaglinide has distinct ß-cell binding site. 
Repaglinide un like glibenclamide dose not stimulate insulin secretion in the 
absence of the glucose. (10,11) 
Table3 shows fasting blood glucose, postprandial blood glucose and 
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Glycosylated Hemoglobin Responses to pharmacological treatment in patients with 
Type 2 Diabetes and table 4 shows effects of pharmacologic treatment of type 2 
diabetes on insulin secretion and glucose production and uptake. (12) 
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Table (3): Fasting blood glucose, postprandial blood glucose and Glycosylated 
Hemoglobin Responses to pharmacological treatment in patients with Type 2 
Diabetes. (12) 
Drug   Decrease in fasting BG 
mg/dl 
HbA1c 
 
Sulfonylureas 40-6o 1.0-2.0% 
 
Metformin 53 1.4% 
 
α-Glucosidase 
inhibitors   
20-30 0.5-1.0% 
 
 
 
Table (4): Effects of pharmacologic treatment of type 2 diabetes on insulin secretion 
and glucose production and uptake. (12)  
Drug Insulin 
secretion        
Hepatic glucose  
Production           
Peripheral 
glucose Uptake   
Sulfonylureas or 
repaglinide 
Increase Slight Decrease     Slight Increase      
Metformin No change      Decrease Increase 
Piolitazone or 
rosiglitazone 
No change       Decrease Increase 
α-Glucosidase 
inhibitors      
No change       No change       No                      
increase 
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2.2 Oral Hypoglycemic action Combinations:- 
Combinations therapy has demonstrated the capability of lowering blood glucose a 
greater amount than one of the agents alone because different classes have 
different mechanisms of action. 
Therapy should be considered in this situation when fasting blood glucose level and 
glycated hemoglobin are not controlled. (1,7) 
2.3 Insulin therapy: 
Insulin is categorized according to their strength, onset and duration of action, 
species source and purity. There are two type of insulin, human insulin and insulin 
synthesis from animal(Until 1980s, insulin was extracted and purified from the 
pancreas of cows and pigs), animal insulins are still in use, but are superseded by 
human insulin.Human insulin is now the main species of insulin in routine clinical 
use. It is usually manufactured by recombinant DNA technology. 
When glycemic control is not achieved by combined oral agents, insulin can be 
used alone or with oral agents (1) (Figure 3). 
Insulins Available Types, Strengths,and Duration of Action* 
Drug                                  Available Strengths           Duration of Action (h)  
Regular                              U-100,100 units/ml                 3-6 
NPH                                   U-100,100 units/ml                 18-24                                   
Ultralente                           U-100,100 units/ml                  24-36 
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Mixtard(70/30)                   U-100,100 units/ml                  12  
*Daily dose and number of doses/day must be individualized  
Fig. (3): Diagramatic approach to managing type 2 diabetes 
Diet and exercise 
Oral monotherapy 
 
Oral combination therapy 
Insulin with or without oral therapy 
 
3- Awareness about hyperglycemia and hypoglycemia:- 
Hyperglycemia when the blood glucose level exceed the renal threshold level of 
180mg/dl( 10 m mol/l)  . 
The patients must be aware about hyperglycemia and symptoms (polyuria, 
polydipsia, polyphagia,  fatigue) from the time of DM diagnosis and how to treat the 
hyperglycemia by these objectives: 
-Taking the medicines in time. 
-Diet control. 
- Physical activity (eg. walking) daily if possible or day by day for 20 mints   . 
- Self monitoring of FBGL, PBGL and HbA1c for control the diabetes. 
The patients also must be aware about hypoglycemia ( blood glucose level less 
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than 50 mg/dl) signs and symptoms are blurred vision, generalized sweating, 
tremor, intense hunger, sweaty palms, a cold feeling, headache, palpitations. 
Hypoglycemia is likely to occure under the following circumstances; 
• Inadequate food intake. 
• With un accustomed physical exercise. 
• Over treatment with insulin or sulphonylureas. 
• Diminishing insulin requirements due to impaired renal function. (7,10,11) 
Means of avoiding hypoglycemic episodes:- 
-Small amount of food intake from 4-6 meals than large amount of 2-3 meals in a 
day.( snacks in between regular meals). 
- When playing extra food intake is increased or dose of antidiabetic agent is 
reduced.  
- Regular laboratory follow up for testing FBG, PPGL and every three month HbA1c 
tested.  
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1.2.5 Prevention and management of diabetes complications:- 
Introduction:- 
The American Diabetes Association estimates that more than 10 million persons 
with diabetes have experienced long term complications. Once these conditions 
develop, they are irreversible. (16) 
Diabetes if untreated or poor treated, induces complications in neurologic and 
macrovascular and microvascular function. 
Evidence now shows that increase in glucose correlate with coronary heart disease 
and that increase HbA1c may be a predictor factor of myocardial in fraction. 
Most diabetes related death result from the long term complications of diabetes 
while 10% resulting from direct acute complications causes such as ketoacidosis 
and hypoglycemia. 
Study results confirm good diabetes management is perhaps the best current 
method of preventing the progression of chronic complications: 
The primary goal of type 2 diabetes management is to lower blood glucose levels to 
prevent the occurrence of macrovascular and microvascular complications which 
has the greatest impact on the morbidity and mortality of patients with diabetes. (16) 
1.2.5.1 Management of macrovascular complications:- 
Type2 diabetes is an independent risk factor for cardiovascular disease in men and 
women. 
Cardiovascular disease is up to four times more common in the diabetic populations 
in comparison to non diabetic populations, and 50% of diabetic people have 
evidence of cardio vascular disease at time of diagnosis. (17) 
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1-Hypertension:- 
Hypertension defined as blood pressure>140/90mmhg , occurs twice as frequently 
in patients with diabetes compared to non diabetic patients and about 50% of  them 
will become hypertensive. 
The relationship between hypertension and hyperinsulinemia is: the second one is 
contribute the pathogenesis of hypertension by decreasing renal excretion of 
sodium, stimulating activity of the sympathetic nervous system and increasing 
peripheral vascular resistance.   
Blood pressure>140/90mmg is a common morbidity of type 2 diabetes, affecting 20-
60% of people with diabetes, depending on age, obesity, and ethnicity. (10) 
 Hypertension is also a risk factor for cardiovascular disease and microvascular 
complications such as retinopathy and nephropathy. 
Randomized clinical trials have demonstrated the benefits of lowering blood 
pressure to <140mmhg systolic and<80mm diastolic in persons with diabetes. 
Epidemiologic analysis show that blood pressures >120/80 mmHg are associated 
with increased cardiovascular event rates and mortality in persons with diabetes. (18 
& 19) 
In the U.K. Prospective Diabetes Study (UKPDS) epidemiological study show, each 
10 –mmHg decrease in mean systolic blood pressure was associated with reduction 
in risk of 12% for any complication related to diabetes and 15% reduction in death 
related to diabetes. (18) 
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Treatment:- 
-Patients with diabetes should be treated to diastolic blood pressure <80 mmHg. 
- Patients with a systolic blood pressure of 130-139 mmHg should given lifestyle/ 
behavioral therapy alone for a maximum of 3 months and then, if target are not 
achieved, should also be treated pharmacologcally. 
- Patients with hypertension (systolic blood pressure >140 mmHg or diastolic blood 
pressure >90 mmHg) should receive in addition to drug therapy lifestyle/ 
behavioral therapy. 
1.1Non pharmacological treatment 
1- Reducing sodium intake.   
Sodium restriction in essential hypertension have shown a reduction in 
systolic blood pressure of 5 mmHg and diastolic blood pressure of 2-3 mmHg 
with moderate sodium restriction (daily intake of 200mmol [4,600mg] 
to100mmol[ 2,300mg ]of sodium ). 
There is better dose response observed with sodium restriction when 
pharmacological agents are used. (18) 
2- Body weight control. 
Several controlled studies have looked at the relationship between weight 
loss and blood pressure reduction. Weight loss can reduce blood pressure 
independent of sodium intake and also can reduce blood glucose and lipid 
level. The loss of one kilogram body weight decreases mean arterial blood 
pressure by 1mmHg approximately. (19) 
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3- Exercise. 
Moderately intense physical activity about 30-45min every day or every other 
day  can lower blood pressure and blood glucose level. 
4- Smoking Cessation: 
1.2 Pharmacological treatment:- 
Treatment diabetic patients with hypertension needs selection of appropriate 
antihypertensive therapy. 
Many available agents can induce adverse effects that pontentiate the risk of 
long term complications such as diuretics like thiazide and ß-blockers which can 
increase serum glucose and lipid levels and increase the incidence of sexual 
dysfunction. Also b blocker first generation non selective and second generation 
ß-1selective antagonists increase insulin resistance, worsen glycemic control 
and induce artherogenic lipid profile by elevating the propotions of small dense 
LDL levels and triglycerides and lower HDL cholesterol. (20 & 21) 
ß-blocker mask the symptoms of hypoglycemia. (20) 
The three groups of antihypertensive agents that are preferable in patients with 
diabetes are: 
 
1-ACE Inhibitors: 
Many studies demonstrate the benefits of ACE inhibitors on multiple adverse out 
comes in patients with diabetes, including both macrovascular and microvascular 
complications, in patients with mild or moderate hypertension in both type 1and 
type2 diabetes the established practice of choosing ACE inhibitors  as first line 
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treatment for diabetes with hypertension. (19) 
The ACE inhibitors exert their beneficial hemodynamic effects through inhibition of 
enzyme that converts angitensin1 to angiotensin 2 in the rennin angiotensin-
aldosterone system. This result decreases the activity of the rennin angiotensin-
aldosterone system as a primary component of the sympathetic adrenergic nervous 
system, these hemodynamic effects lead to reduction of peripheral resistance also 
affect the vessels of the kidneys. 
Vasodilatation of both efferent and afferent renal vessels promotes improve renal 
blood flow and glomerular filtration. In these patients renal insufficiency results from 
hyperadrenergic activity. 
The ACE Inhibitors has no adverse effects on glucose tolerance or lipid profiles and 
also they have no effect on sexual functions and improve diabetic nephropathy with 
diabetes. (20) 
Side effects like cough and increasing serum creatinin level above normal limit are 
major side effects, if these side effects observed in patients treated by ACE 
Inhibitors are shift to ARBs agents to overcome the side effects. 
 
2-Calcium Channel Antagonists: 
These agents act by causing peripheral vasodilatation, which is associated  with 
less reflex tachycardia and fluid retention than other vasodilators. They are effective 
as single-drug therapy in all demographic groups and grades of hypertension. They 
may be preferable to beta blockers and ACE inhibitors in blacks and old patients. 
Calcium channel blockers and diuretics are less additive when given together than 
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when either is combined with beta-blockers or ACE inhibitors. How-ever, Verapamil 
and diltiazem should be combined cautiously with beta-blockers because of their 
potential for depressing atrioventricular conduction and sinus node automaticity as 
well as contractility.  
Verapamil and Diltiazem preferable agents than Nifidedipine, because it has been 
reported that Nifidedipine has a possible increase protein level in the urine and also 
may exert a mild hyperglycemia in hypertensive diabetic patients. (22) 
This type of antihypertensive like ACE, they have no adverse effects on serum lipid 
or cause impotence in men.  
The most common side effects of calcium channel blockers are headache, 
peripheral edema, bradycardia, and constipation. The Dihydropyridine agents that 
mainly have been used in Sudan include Nifidepine and Amlodipine. 
 General side effects are: vasodilatation, headache, flushing, palpitations and 
peripheral edema. 
Calcium channel blockers have negative inotropic effects, may cause heart failure in 
patients with cardiac dysfunction. This is not observed in Amlodipine which is the 
only calcium channel blocker which are safe in this situations. 
3-Third generation ß blockers: 
The side effects that associate with ß blockers can be avoided by choosing anon 
selective ß blockers with α-blocking properties.  
Anon selective ß blockers with α -blocking properties(eg Carvediol) maintain insulin 
sensitivity disposal, while decrease triglycerides levels and increase HDL levels also 
but its  use in limited by postural hypotension.(23) 
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2- Hyperlipidemia: 
Hyperglycemia induces the excessive release of  insulin from the pancreas and this 
leads to hyperinsulinemia which contributes to syndrome x and then long term 
exposure of the body patients to elevated glucose increases indothelium 
dysfunction which lead to development of atherosclerosis. (17) 
According to the Centers for Disease control and Prevention, 97% of adults with 
diabetes have one or more of lipid abnormalities.(17) 
Dyslipidemia in type 2 diabetes have elevated triglyceride, decrease in HDL 
cholesterol levels and small oxidized LDL cholesterol levels which may increase 
atherogeniciy. 
According to current ADA recommendations, the major emphasis for treating 
diabetic dyslipidemia should be placed on lowering LDL cholesterol levels 
to<100mg/dl even in patients with no history of CVD(17), triglycerides to<150mg/dl 
and raise HDL cholesterol to >40 mg/dl. 
 
Treatment:- 
1 .Non pharmacological treatment:- 
1.1 Nutritional interventions include: 
Advising patients to avoid any diet nutrition that increases cholesterol level in the 
blood like saturated fats: butter,  fatty meat and full fat dairy products and to advice 
patients to replace it with poly unsaturated and mono unsaturated fats to help them 
in lowering the cholesterol level in the blood , mono unsaturated fats found in olive 
oil and rapeseed oil and there is also a wide range of margarine and low fats 
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spreads based on mono unsaturated fats. Poly un saturated fats include sunflower, 
corn oil and Soya oil, some margarine and low fats spreads. Oily fish such as 
mackerel, sardines (are higher in fats but has special type of poly unsaturated fat 
known as omega 3. This type of fats lower triglycerides and protect the patients 
from  heart attacks so the patients should be adviced to eat oily fish twice a week.  
Choose low fat dairy food such as skimmed or semi skimmed milk, low fat yoghurt, 
cheese, ice cream and custard.  
Choose lean meat /mince and skinless chicken / poultry and trim all visible fat 
before cooking. 
Use low fat cooking methods such as grilling, barbequing, stir-frying, dry roasting or 
poaching. 
Skim the fat off the top of cooled casseroles, stews and curries. 
Cook with mono unsaturated oils and spreads like olive, rapeseed and ground and 
nuts oils. 
Choose tomato based sauces rather than creamy sauces, avoid creamy style 
soups.   
1.2 weight loss and excersise: 
Weight loss and exercise is the cornerstone in the management of dyslipidemia in 
patients with diabetes which increase the insulin sensetivity reduce  triglycerides 
level, LDL cholesterol and cholesterol level. 
Excersising enhances weight loss and increases HDL cholesterol level. 
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2. Pharmacological treatment:- 
Pharmacological treatment is indicated if there is no response to life modifications 
and no control of glucose in the blood. 
The first priority of pharmacological therapy is to lower LDL cholesterol to a target 
goal of < 100mg/dl. 
For LDL lowering, Statins are the drug of choice. Statins raise HDL modestly, but a 
greater reduction is achieved with Fibrates. 
In patients with LDL between 100 mg/dl and 129 mg/dl, a variety of treatment 
strategies are available, including more aggressive nutrition intervention and 
pharmacological treatment with a Statins. In addition, if the HDL is <40 mg/dl and 
the LDL is between 100 and 129 mg/dl, a Fibric acid derivative might be used. 
In general drug act to reduce the concentration of cholesterol within hepatocytes, 
causing a compensatory increase in low- density lipoprotein- (receptors LDL R) on 
their surface, and increase up take of cholesterol rich LDL particles from the blood 
stream. 
Statins:- 
These agents block the rate-limiting enzyme for endogenous cholesterol synthesis, 
hydroxyl-methylglutary coenzyme A (HMG CoA) reductase. This results in 
increased synthesis of LDL-receptors (up regulation) in the liver and increased 
clearance of LDL from the circulation, plasma total cholesterol and LDL –cholesterol 
fall to attain a maximum effect 1 month after commencing therapy All statins cause 
a dose dependant reduction in total and LDL-cholesterol although  there are 
difference in  their therapeutic efficacy: for example, at their starting dose LDL-
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cholesterol falls by average of 17%with 28% with Simvastatin (10 mg /d )and 38 % 
with Atorvastatin(10 mg /d ).  
There is no intolerance to continued administration of statins, their efficacy in 
primary and secondary prophylaxis of hypercholesterolemia is probably a class 
effect although long term outcome studies are not available. 
Statins are more effective when given in the evening and well absorbed after 
administration orally, and are metabolized in the liver. 
 They are well tolerated, the commonest adverse effect being transient abnormality 
of liver function tests in some 1% of patients. 
Combination therapy, with a Statins and Fibric acid or Statins and Niacin, may be 
efficacious for patients needing treatment for all three lipid fractions, but this 
combination is associated with an increased, risk for abnormal transaminase levels, 
myositis, or rhabdmyolysis. 
1.2.5.2. Management of microvascular complications: 
1- Nephropathy 
Nephropathy  in diabetes is defined as persistent protienuria, decreased glomerular 
filtrations and increase arterial blood pressure.  
Diabetic nephropathy is the most common cause of newly diagnosed end stage 
renal disease in the USA, 35% of diabetic patients will develop nephropathy and 
increasing death rate after ten years from 50% to 75% after diagnosing nephropathy 
in diabetes. Mean that about 14,000 patients will develop end stage diabetic 
nephropathy annually. (24) 
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Poor glucose control increases intragolumerular pressure which results in 
glomerular hyperfiltration. 
Factors that can contribute to nephropathy are hypertension, hyperlipidemia, poor 
glucose control and smoking.  
Another factor that correlates with the progression of renal disease in diabetes is 
the presence of miroalbuminuria. 
Microalbuminuria represents an abnormally elevated urine albumin level .The 
presence of microalbuminuria predicts worsening of renal disease to overt diabetic 
nephropathy and elevated risk of cardiovascular disease. Up to30 % of people with 
newly diagnosed type2 diabetes will already have abnormally high urine albumin 
levels; about75% of these patients will have micoalbuminuria and about 25% will 
have overt diabetic nephropathy. 
Early detection of microalbuminuria through screening allows interventions that aim 
at preventing diabetic nephropathy. (25) 
It is recommended that in all type 2 diabetes detect microalbuminuria from the first 
diagnosis of diabetes and after 3month, 6month and screen annually for patients 
who have microalbuminuria.(18)  
Good glycemic control can prevent progression to microalbuminuria. Preventing the 
progression of each step of renal disease in patients with diabetes 
microalbuminuria, diabetic nephropathy, and end stage of renal disease or death 
can be achieved with blood pressure control and use of angiotensin based therapy 
such as angiotensin converting enzyme inhibitors and angiotensin II receptor 
blockers. (25) 
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Primary prevention preventing microalbuminuria can be achieved through good 
glycemic control and blood pressure control and through using of an angiotensin 
converting enzyme inhibitors in both type 1 and type2. 
Secondary prevention to the progression from microalbuminuria to diabetic 
nephropathy can be achieved with an ACE inhibitor in both type 1 and type 2 
diabetes and with angiotensin II receptor blockers in type 2 diabetes.(25) 
Tertiary prevention is; preventing the progression of diabetic nephropathy to end 
stage renal disease by angiotensin II receptor blockers in type 2 diabetes. 
Once microalbuminuria is diagnosed in patient with diabetes, patients need lowering  
of blood pressure to  below 130/80mmHg. The target of low density cholesterol level 
should be below 2.5 mmol/L and smoking cessation should be mandatory.(25) 
2- Retinopathy:- 
Diabetic retinopathy is the leading cause of newly diagnosed blindness in the United 
States. Good glycemic control significantly slows the progression of retinopathy. 
Diabetes related retinopathy may be either non-proliferative or proliferative.  
Non proliferative develops with little vision impairment while proliferative retinopathy 
can greatly diminish vision causing sudden blindness.(24) 
 
 
 
 
 
 
  
38
3- Lower limb amputitions: 
Foot care:- 
Amputations are surgical procedures which are often indicated when there is 
gangrene, peripheral arterial occlusion, non healing ulcers, sever soft tissue 
infections, osteomyllities, trauma, tumors and deformities.  (25) 
Diabetic foot ulcers usually occur in the 6th decade of life among type2 diabetics 
with more than 5 years duration of illness.(24) 
Foot complications are one of the most serious and costly complications of 
diabetes. However, through a care strategy that combines prevention and multi-
disciplinary treatment of foot ulcers; appropriate organizations; close monitoring, 
and the educations of diabetic and health care professionals, it is possible to reduce 
amputation rates by between 49% and 85%. 
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1.3 OBJECTIVES OF THE STUDY 
 
1.3.1 General main objective 
Aim: To assess the impact of the Pharmaceutical Care plan in type 2 diabetic 
patients in Khartoum State:  
 
1.3.2 Specific objectives 
1. To compare the result of the study group before and after six-months of the 
study. 
2. To measure the risk factor associated with study group when compare with 
control group.  
3. To identify the drug therapy problem that may alter control of study group. 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Time and place of study: 
The study was carried out in Jaber Obu Eliz Center for Diabetic Patients in 
Khartoum state from May 2004 until May 2005.  
2.1.2 Study populations: 
Twenty six diabetic patients at ages40-60 years old, were randomly chosen from 
out patients clinic(All of these, twenty patients have been selected for good clinical 
attendance and follow up for 6 months). A control group of 37 was selected from 
different social activities between ages40-60 years. Venous blood and Urine 
samples were taken to measure different parameters. These were compared with 
the recommendations of The American Diabetes Associations 2002 and WHO 
reports for individuals with normal value. (7,12) 
2.1.3 Sample size 
Any cases included in the study were selected from out patients seen in the clinic 
from September1, 2004- September 30, 2004.  
2.1.4 Study design 
Case control study.  
2.1.5 Inclusion Criteria of the control group- 
Individuals with normal value selected according to the recommendations of The 
American Diabetes Associations 2002 and WHO reports. (7, 12) 
2.1.6 Exclusion Criteria of the control group 
Individuals with abnormal value were excluded according to the recommendations 
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of The American Diabetes Associations 2002 and WHO reports for individuals with 
normal value. (7,12) 
2.1.7 Inclusion Criteria of the study group 
Patients with type2 diabetes for less than fifteen years.  
2.1.8 Exclusion Criteria of the study group 
a. Patients with type2 diabetes for more than15 years. 
b.Type 1 diabetes. 
c.Pregnant women.  
2.1.9 Laboratory investigation:-  
After fasting over night for 12 hours, blood sample and urine samples were 
collected from the study group. 
1-About 5 ml venous blood sample was taken from the study group and divided into 
3 tubes as follows: 
i.1ml  in tube1containing fluoride oxalate to determine the fasting blood glucose 
level. 
ii.1 ml in tube2 containing EDTA to determine Glycolyted heamoglobin (HbA1c 
value). 
iii.3ml in tube3 blank container to separate serum to determine the Total cholesterol 
(TCH), High density lipoproteins level (HDL), Low density lipoproteins level (LDL) 
and Triglycerides (TG).  
2-Urine samples were taken from the study group to determinate the 
Microalbuminuria (MICR).  
3-After 3 month the following parameters were determinated for the study group: 
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a-Post prandial glucose level. 
b-Liver function test by  determining albumin and the enzymes SGPT, ALP and 
SGOT. 
c-Serum creatinine. 
d-Serum potassium. 
These parameters were determined by using standard laboratory methods 
(Appendix D). 
2.2.10 Questionnaire 
Twenty six diabetic patients of type 2 diabetes were requested at the beginning of 
study to answer a questionnaire used to interview the study group. It was written in 
English language and translated into Arabic language to the patients. The data 
obtained was based on Royal Pharmaceutical Society Practice Guidance for 
community pharmacists on the care of people with diabetes (Appendix A).  
2.2.11 Education 
After the laboratory investigation were completed. Each patient with special 
emphasis was given a printed information on (Appendix C): 
a. pathophsiology of diabetes, about hypoglycemia, hyperglycemia and how to treat 
them.  
b. the relationship between drugs, diet control and physical activities on the 
treatment of diabetes,  
c. meal planning contained information about the content of the different types of 
carbohydrates, fats, proteins in international percentage unit, 
d. importance of exercise day after day (eg. walking for 20minutes).  
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e. importance of yearly examination of foot, eye and dental care.  
During the monthly clinic visit the study group were referred to an endocrinologist 
for management and further monitoring. Also they had individual educational 
consultation with the pharmacist to ask or to get clarification on any questions about 
their drug regimen, nutritional responsibilities, exercise provisions and they also  
received a refreshment of that information was mentioned above. 
 
2.2.12  Flow chart sheet 
A patient flow chart sheet was completed by the pharmacist for each patient to 
assess the outcomes of the intervention. (Appendix B) 
2.2.13 Statistical analysis: 
Data was expressed as means + standard deviation (SD). 
Numerical values were compared before the study, after 3 months and after 6 
months respectively with the study group. Variance (Anova) was used for statistic’s 
evaluation.  
The SPSS (Statistical Package of Social Study) was used for analyzing the data 
collected, the out put was converted into charts by using the Microsoft Excel 
programme.  
Risk factor estimated by measure cross-tabulation for the study cases with control 
cases to measure odd ratio before and after 6 months. 
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3. RESULTS 
 
Twenty six cases in the study were carried out by the pharmacist on intervention 
study, which was approved by the consultant endocrinologist. All of these twenty 
patients have been selected for clinical attendance and follow up for 6-months.  
1-Patients’ criteria at the time of entering the study: 
The socio-economic status of the study group was as follow: 8(40%) patients were 
employees, 1 (5%) patients was a teacher, 7 (35%) patients were housewives and 4 
(20%) patients were free traders.  
The number of patients who were school-educated was 9 (45%), university 
educated were 9 (45%) and postgraduates were 2 (10%) patients.  
Patients’ medical history was shown in table (5).Non-pharmacological measures for 
the study group was shown in table (6).  General knowledge about BMI, health 
nutrition, physical activity and foot care for the cases and self-monitoring were 
shown in table (7 & 8).  Tables (9, 10, 11, 12 & 13) show the pharmacological 
measures for the study group. 
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Table (5): Shows patients’ medical history 
Patients’ medical history 
Male/female  9/11 
Duration of diabetes  4 + 3.4 
Last FBGL was performed  165 + 48.2 
Body mass index  26 + 4 
Normal weight<25  5 (25%) 
Over weight<30  8 (40%) 
Obese>30   7(35%) 
Family history of diabetes                              13 (65%) 
Smoker                                                            
                                                                 
1 (5%) 
Type of pervious treatment used                                                
Diet.  4 (20%) 
Sulphonylureas .                        9(45%) 
Sulphonylureas+ Biguanides.  2(10%) 
Sulphonylureas+ Biguanides+ Antihypertensive treatment. 2(10%) 
Sulphonylureas + Antihypertensive treatment.                           1(5%) 
Biguanides+ Antihypertensive+ anti asthmatic treatment. 1(5%) 
Biguanides+ Antihypertensive                                                      1(5%) 
Other disease beside diabetes:                                                  
Hypertension  5 (25%) 
Bronchial Asthma                                                                         1 (5%) 
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Table (6): Non-pharmacological measures of the study group 
Non-pharmacological measures Frequency Percent. 
-Patients were advised for diet control  :                      
On daily diet control were found.                                7 35% 
Once a week were on diet control.                             3 15% 
-Patients were not advised for diet control. 10 50% 
-Patients were advised for weight control.  10 50% 
Once a week on weight control.                                 2 10% 
-Patients were not advised for weight control. 10  50% 
-Patients were advised for foot care:   
On daily foot care.                                     3 15% 
 Once a week on foot care.                                        5  25% 
Patients were not advised for foot care. 12 60% 
-Patients were advised for eye care. 7  35% 
-Patients were not advised for eye care. 13  65% 
-Patients were advised for dental care. 5  25% 
-Patients were not advised for dental care. 15 75% 
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Table (7):Show General knowledge about BMI, health nutrition, physical 
activity and foot care for the cases  
General knowledge  No. of cases knew Percent. 
Ideal body mass index           3 15% 
Health nutrition                      11 55% 
Physical activity                     11 55% 
Foot care                               4 20% 
 
 
Table (8): Show  lab and glucometer monitoring of the study group  
Type of  monitoring                                Number of cases Percent. 
Monitoring by lab and glucometer                4 20% 
Monitoring by lab:  12 60% 
a-By lab once a month monitoring. 6  30% 
b-Not regularly  monitoring by lab                6 30% 
Never monitoring by lab and glucometer     4 20% 
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Pharmacolgical measures of the study group: 
Table (9): Shows source of the drug from the pharmacy and the counseling.  
Source & Counseling of the drug No. of cases Percent. 
Source of the drug from pharmacy                16  80% 
Counseling about drug administration             16  80% 
Counseling about drug administration by:   
 Pharmacist                                               1  5% 
 Physician                                                 1  5% 
 Nurses                                                     1  5% 
Pharmacist, Physician and Nurses                 8  40% 
Pharmacist and Physician                               2  10% 
Physician   and Nurses                                   5  25% 
 
Table (10): General knowledge about signs and symptoms of hyperglycemia and 
hypoglycemia: 
Signs and symptoms of hyperglycemia No. of cases  
 found knew 
Percent.  
Polyuria, tiredness, nocturia, blurred visions 
thirsty and polyvagia 
       14  70% 
Tiredness                                                                   2 10% 
Tiredness and nocturia                                               4 20% 
Frequency of the symptoms:   
Rare                                                                           9 45% 
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Occasionally                                                     3 15% 
Sometime                                                         7 35% 
All the time                                                        1 5% 
Signs and symptoms of hypoglycemia:   
Sweating                                                  7 35% 
Sweating and headache                            1 5% 
Sweating and palpitations                          3 15% 
Anxiety, sweating and palpitations  
Cases that found not know               
1 
8 
5% 
40% 
Frequency of the symptoms:   
Rare*                                                        12 60% 
Occasionally*                                              1 5% 
Sometime*                                                3 15% 
 
*Rare (Once a month) *Occasionally (Once a week)  *sometime(Once a day) 
Table (11): Patients knowledge about hyperglycemia and its treatment. 
 
 
No. of cases Percentage
Poor knowledge  about treatment.                       2 10% 
Good knowledge about treatment.                       1 5% 
 Excellent knowledge about treatment.  
 
Never  known                           
0 
 
17 
0 
 
85% 
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Table (12): Patients knowledge about hypoglycemia and its treatment. 
 No. of cases Percentage
Poor knowledge about hypoglycemia 
treatment.                                 
7 35% 
Good knowledge                                  0 0% 
Excellent knowledge  
 
Never  known                                             
0 
 
13 
0% 
 
65% 
 
 
 
Table (13): General knowledge of pathophysiology.   
 
general knowledge of pathophysiology No. of cases 
found were 
knew 
 
Percentage 
Increase glucose in the blood              14 70% 
Increase glucose in the blood, Decrease 
insulin sensitivity and the pancrease defects
1 5% 
Increase glucose in the blood and the 
pancrease defects 
2 10% 
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2-Biochemical Parameters Results: 
After the 3-months and 6-months from the study, following parameters were 
measured: Hb1c value, lipid profile (total cholesterol, HDL, LDL and TG) 
Microalbumin and creatinine ratio were measured before and after the study. 
The means + standard deviation (SD) of investigation parameters between study 
group and control group are shown in table14.  
Table (14): shows the results of the HbA1c value, lipid profile (total cholesterol, 
HDL, LDL and TG) Microalbumin and creatinine ratio for the study group were 
measured before and after 3months and 6 months of the study in addition a as well 
as the result of the same parameters of the control group.  
Table (14) means difference of investigation parameters between the study group 
and control group. 
Parameters Control group Study group After 3 months After 6 months
Hb1c 4.1± 0.7 10.3± 2.4 7.4 ± 2 7.8±1.3* 
TCH 159± 27 198± 43 185± 39 184±29* 
HDL 42± 9 43± 7  40± 8 52± 11* 
LDL 96± 28 125± 36 119± 36 103± 28* 
TG 131± 28 201± 87 156± 74 135± 43* 
MICR 15± 7 22± 18 0000 12 ± 7* 
*Statistical analysis shows that values of Hb1c, HDL,TG, MICR tests significant at p 
value <0.05 and not  significant for tests TCH, LDL and FBGL tests at p value 
>0.05.  
Figure4 shows the study group parameters before and after the study. 
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2- After the 3-months and 6-months interventions and treatment, the cases reached 
the normal and abnormal values shown in table 15.  
Table (15): shows normal and abnormal values of the different parameters of the 20 
cases before and after3-6 months. 
Before study After 3 months of study After 6 months of study  
Parameters Normal Abnormal Normal Abnormal Normal Abnormal  
Hb1c 2 (10%) 18 (90%) 7 (35%) 13 (65%) *6 (30%) 14 (70%) 
TCH 8 (40%) 12 (60%) 13 (65%) 7 (35) *14 (70%) 6 (30%) 
HDL 17 (85%) 3 (15%) 15 (75) 5 (25%) *20(100%) 0 (0%) 
LDL 12 (60%) 8 (40%) 11 (55%) 9 (45%) *14 (70%) 6 (30%) 
TG 11 (55%) 9 (45%) 16 (80%) 4 (20%) *17 (85%) 3 (15%) 
MICR 15 (75%) 5 (25%) 0 0 *20(100%) 0 (0%) 
*Statistical analysis shows P values of Hb1c 0.00 1, HDL 0.02, TG 0.01 and MICR 
0.02 are significant but tests FBGL 0.71, TCH 0.65 , LDL 0.24 are not significant.  
The figures 5, 6, 7, 8, 9 and 10 show the normal and abnormal values of the 
investigation parameters before and after 6-months.  
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3- The odd ratio was measured after 6-months to measures the risk factor 
associated with the study group satisfactory glycemia control (Hb1c<7) affected 6  
cases (odds ratio0.33 95% CI 0.08, 1.46). Satisfactory total cholesterol control 
(TCH<200 mg/dl) affected 14 cases (odds ratio0.57, 95% CI 0.31, 1.05). 
Satisfactory (LDL<100 mg/dl) control affected 14 cases (odds ratio 0.86, 95% CI 
0.54, 1.36). Satisfactory (TG<150 mg/dl) control affected 17 cases (odds ratio 0.65, 
95% CI 0.42, 1.00). Satisfactory (HDL>35 mg/dl) control affected 20 cases (odds 
ratio 0.85, 95% CI 0.71.02). Satisfactory (MICR>30) control affected 20 cases (odds 
ratio 0.75, 95% CI 0.58, 0.97). 
Table (16): The odd ratio measured after 6 months for controlled and non controlled 
cases 
Parameters No. of 
cases 
controlled 
OR (95% CI) No. of cases 
non controlled  
OR (95% CI) 
Hb1c < 7mg/dL 6 0.33 (0.08-1.46) 14 1.286 (0.93-1.7) 
TCH <200mg/dL 14 0.57 (0.31-1.05) 6 2 (0.94-1.05) 
HDL > 35mg/dL 20 0.85 (0.71-1.02) 0 0 
LDL < 100mg/dL 14 0.86 (0.54- 1.36) 6 1.33 (0.57-3.15) 
TG  < 150mg/dL 17 0.65 (0.42-1.00) 3 3 (0.95-9.48) 
MICR > 30 20 0.75 (0.58-0.97) 0 0 
 
 
Figure (11,12) show the odd ratio of controlled group(cases) and non 
controlled after 6 months of the study. 
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3- Evaluation of side effects and adverse drug reactions:-  
Liver function test was carried out for cases managed by Sulphonylurea and 
Atorvastatins. Serum creatinine was carried out for cases manage by Metformine 
and Lisinopril after 3-month of the treatment. 
            According to these findings, cases found without serious adverse effects continued 
the treatment, but those with sever or harmful adverse drug reactions were 
managed either by reducing the dose or changing the drug.  
Anti hyperglycemia agents: 
Oral antidiabetic drugs are used for non insulin-dependant diabetes mellitus in 
patients who do not respond to dietary adjustment and an increase in physical 
exercise. 
The most common used of oral antidiabetic agents are Sulphonylurea and the 
Biguanide (Metformin), they may occasionally lead to hypoglycemia 4 hours or more 
after food. This may be dose-related and usually indicates excessive dose and it 
occurs more frequently with long-acting Sulphonylurea such as Glibenclamide, 
caution is required in the elderly and those with renal or hepatic insufficiency 
because of the risk of hypoglycemia. (8) 
Metformin is used as first line treatment in over weight and in patients treated by 
diet or Sulphonylurea have failed to control the disease. Metformin may provoke 
lactic acidosis(8) which is most likely to occur in patients with renal impairment, it 
should not be used in patients with even mild renal impairment. 
As shown in table17 there is two patients on Sulphonylurea treatment felt  
palpitations and sweating, they found that poor dietary control for that reason they 
  
64
educated to take small meal in 3-4 times a day rather than to take large meal in 2- 
times a day. One patient was going on vomiting on the treatment of Metformin, her 
serum creatinine found >150mg/dl, after that her drug treatment was changing to 
another type (Metformin should be excluded in patient with serum creatinine >150 
mg /dl). (8) 
Two patients also on treatment of Metformin developed palpitations and sweating, 
their dose was decreased. 
Anti hyperlipidemia agents: 
Statins  are well tolerated and the commonest adverse being transient and usually 
due to minor abnormality of liver function tests(8), liver function test was found in 
normal range for all cases treated with Atorvastatins. 
Anti Hypertension agents: 
One patient on the treatment 0f nifidipine 20 mg bid, he shifted to Lisinopril 5 mg a 
day in the evening for 3-months. His blood pressure150/90 after three months 
became 140/90. 
A patient on the treatment of Nifidipine and Atenalol was found uncontrolled, 100 
mg of Atenalol once a day indicated for 3 months.  
During the study was observed that his HDL decreased from 45mg to 28 
mg/d(Atenalol decreased HDL in the blood) (8), his dose was decreased from 100 
mg into 50 mg, another treatment indicated was  Lisinopril 5 mg,  increased after 
one month into 10 mg to control the hypertension,  
 then it became 140/90.  
Patients on treatment with Lisinopril (Lisinopril may cause hyperkalemia) (8), serum 
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K+ was measured for them, which was found in normal levels.    
Anewly diagnosed diabetic was known hypertensive for two years , when came to 
the clinic, she was uncontrolled, on the treatment of Nifidipine 1o mg bid, the dose 
was changed to 20 mg bid for 3 months  
 She complained  a neck pain with severe pain headache (Nifidipine may cause 
headache and neck pain in some patients) (8), when came after one month, she 
stopped the treatment by herself, for that reasons indicated for her Atenalol 50 mg 
bid.  
Apatient was asthmatic on the treatment of 50 mg Atenalol (Atenalol contraindicated 
in asthmatic patient) (8), her blood pressure was measured =135/85 , the drug was 
excluded by the consultant and she was educated to take  low salt food, she 
followed for 3-months and 6- months and blood pressure was 135/80. 
One patient was felt nocturia on the treatment of Atenalol and Sulphonylurea the 
FBGL was found under the 180 mg /dl. 
The consultant decreased the Atenalol dose and in addition he was taken 
Metformin, symptom was disappeared. 
Every patients were well controlled   measured their blood pressure every 3months 
and with poor controlled every month.  
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Table (17): Side effect and adverse drug reaction was found in some cases.  
 
 
 
 
 
 
 
No. of cases Drug  Daily 
amount 
Side effects Drug 
interactions 
Adverse drug reactions 
One cases felt  these 
Side effects 
GLIBENCALA
MIDE 
 15 mgbid Palpitations and 
sweating 
  
One cases felt  these 
Side effects 
GLIMPRIDE  6 mgbid Palpitations and 
sweating 
  
One cases was 
found followed these 
Adverse drug 
reactions 
ATENALOL  1oomg od   Increased glucose in the 
blood, decreased HDL in 
the blood.  
One cases felt these 
Side effects   
NIFEDIBIN  20 mgod Headache and 
neck pain 
  
One cases was 
asthmatic    
METFORMIN 
and 
ATENALOL 
 500mg tds 
 
Palpitations    Contraindicated  
for asthmatic patients. 
 One cases found 
her serum 
creatinine>150mg/dl   
METFORMIN  850mgtds 
 
Vomiting(serum 
creatinine>150mg
/dl) 
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4. DISSCUSSION 
 
The development of the professional guidelines to enable pharmacists to develop 
their practice in the care of the patients with type 2 diabetes is based on firm 
evidence that attaining specific treatment goals are associated with improved 
outcomes. (14) 
Improvements in the primary care multidisciplinary services to diabetic patients are 
dependant on the development of databases and implementation of protocols 
designed to address individual patient pharmaceutical care needs.  
 knowledge about the treatment of type 2 diabetes by increasing their patients in 
making changes in their nutritional habits, increasing  patients general knowledge 
on educating them ; the appropriate physical activates in promote weight loss to 
improve insulin sensitivity  and has a benefit effect in reduction cholesterol level and 
decreases blood pressure, medicine intake in time is important for control the 
diabetes, educated them in the relationship between the drug, diet control and 
physical activities on the treatment of diabetes. 
The results were statistically analyzed for HbA1c (Glycosated heamoglobin), HDL 
(High density lipoproteins level), TG (Triglycerides) and MICR (Microalbuminuria) 
which were found to be significant at (p < 0.05) where as for FBG (Fasting blood 
glucose), TCH (Total cholesterol), and LDL (Low density lipoproteins level) were not 
significant (p> 0.05 ).  
The results of the present study of HbA1c were  found to be  in agreement with the 
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study carried out over one year in Darlington hospital NHS Trust in UK as reported 
by Labib et al (14) The pharmaceutical care plan for both studies was almost similar.  
However, the adjustments of diabetes of the maximum effective dose in our study 
was based on measuring blood glucose level in the laboratory where as for the 
other study the patients were educated to measure blood glucose level by using 
glucometerdrug and counseling them how to use their medicines ,patients 
individually was educated on regarding diabetes complications and how to treat the 
complications of hypoglycemia and hyperglycemia and to be aware of diet and 
exercise management. While difference between two studies was on the above 
study, cases were found on the maximum dose of the drug treatment, all patients 
individually educated to use glucometer.  
Our results of HbA1c, however, differ from the findings reported were found to be 
significant which was not agreement with the finding of study published by Edward 
and coworkers (15). Nevertheless the two included information on signs, symptoms, 
treatment of diabetes, importance of clinical attendance. However our results un like 
those of Edward and his colleagues did not include other types of diabetes.  
Risk factor associated with the study cases which was completeness the primary 
care medical records after 6months from the study, The results were found 100% 
satisfactory control for tests HDL and MICR, 30% satisfactory control for Hb1c, 70% 
satisfactory control for tests TCH, LDL and 85% satisfactory control for test TG.  
when compared this result with the result of study presented at the British 
Pharmaceutical Conference,Birmingham,2000 reported by E.Douglas et tal. over 12 
months, completeness of clinical data recorded: unsatisfactory glycemic control 
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(Hb1c>8) affected42% (odds ratio3.9, 95% CI 1.5, 10.1) associated with age<64 
years while in this study unsatisfactory glycemic control (Hb1c>8) affected70% 
(odds ratio1.286 CI 0.93- 1.7) associated with ages beteen40-60 years.   
 Evaluation and identification of the drug problems associated with the study group 
during the course of treatment showed that no serious adverse effect occurred, 
however few cases of some adverse effects were encountered. These were 
managed mainly by reducing the dose as shown in table (17). 
In some cases no improvement was observed during the study which was found to 
be due to discontinuation of the treatment. This was either due to financial reasons 
or due to the belief by the patient that the drug was harmful. Both cases were 
managed either by supplying the drugs or by convincing the patients about the 
safety of drugs by laboratory investigations.   
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5. CONCLUTION & RECOMMENDASIONS 
 
5.1 Conclusion:  
The development of the professional guidelines to enable pharmacists to develop 
their practice in the care of the patients with type 2 diabetes is based on firm 
evidence that specific treatment goals are associated with improved outcomes. 
Improvements in the primary care multidisciplinary services to diabetic patients are 
dependant on the development of databases and implementation of protocols 
designed to address individual patient pharmaceutical care needs.  
Intervention by the pharmacist, along with other health care professionals aided in 
the reduction of the prolongation of type2 diabetes through; 
• Life changes; involving nutrition, physical activity, drug treatment and the 
relations between them on the treatment of type 2 diabetes. 
• Educated the study group on the important of the foot, eye dental care 
• Increasing the quality of life. 
• An integral component of pharmaceutical care is the formation of the 
therapeutic relation between the pharmacist and the patient.  
The research revealed that it is essential that patients develop a trusting and 
collaborative relationship with the pharmacist, as well as other health care providers 
to achieve maximum pharmaceutical care and improve quality of life of twenty 
patients.  
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5.2 Recommendasions: 
? Educational and preventive programs regarding  type 2 diabetes are the 
responsibility of the pharmacist as well as other health care team in the 
Sudan. 
? Educational programs and awareness about diabetes are important in 
patient-families and the society which is force power for the communities that 
may help to control diabetes complications. 
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Limitations 
 
1-It seems that poor awareness of the study group about the hypoglycemia and 
hyperglycemia may carry information bias.   
2- Because the study was done over 6-months, it seems to be very difficult to 
measure the effects of the education on foot, eye and dental care. 
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Appendix A 
(A) Demographic   Data:- 
       Date: ………………………… 
1- Name: . ………………………………………………………………………….. 
2- Age: ………………………………………………………………………………  
3- Height: …………………………………………………………………………… 
4-Weight: ……………………………………………………………………………. 
5-Gender                a) Male                     b) Female 
6-Occupation: ……………………………………………………………………….       
7-Educations       a) school        b) university      c) postgraduate      d) none      
8-Adress: …………………………………………………………………………. 
 (B)Patient Medical History:- 
1-Do you know what diabetes is: 
a) Affect the pancreas organ   
b) Decrease the cell sensitivity   
c) Increase blood glucose level 
2-When the first time diagnose diabetic? 
3-What type of drug used? 
a- Diet  b- Sulphonylureas   c- Biguanides 
d- Insulin e- Others 
4-Have you been monitored your blood glucose? 
a) Yes:                                      b) No: 
4.1 If yes what type:   
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a) By Lab             b) By glucometer 
4.2 I f by lab: 
a) Monthly                  b) Not regularly  
6-Do you know a bout:  
a) Ideal body mass index (BMI)   a) Yes               b) No 
b) Healthy nutrition                       a) Yes               b) No 
c) Physical activity                        a) Yes               b) No 
e) Foot care                                    a) Yes              b) No 
7-What are the signs/symptoms of hyperglycemia? 
a) Polyuria           b) nocturia        c) blurred visions    d) tiredness     
e)Thirsty              f) poly fagia 
7.1-How frequent are the symptoms: 
a) Rare          b) occasionally       c)Sometimes        d) all the time 
8-When the last blood glucose test performed and what was the value? 
……………………………………………………………………………………….. 
………………………………………………………………………………………… 
9-What are the signs/ symptoms of hypoglycemia? 
a) Anxiety       b) nervousness         c) palpitations        
d) sweating  e) Headache         f) confusion                      
g) visual disturbances. 
9.1.- How frequent are the symptoms 
a) Rare                        b) Occasionally                  
c)Sometimes           d)all the time 
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10-Do you have others diseases beside diabetes?  
a) Yes:                                      b) No: 
11-If yes which of the following 
a) Hypertension    b) Hyperlipidemia       
c) Cardiovasculardisease        d) others 
12-family history of diabetes:  
a) Yes:                                      b) No: 
13- Smoker                              
a) Yes:                                      b) No: 
 (C ) Management of diabetes:- 
1-Non-pharmacological measures: 
1.1. Is there diet control: 
        a) Yes:                b) No: 
1.1.1. If yes how long this takes place: 
a) Daily                  b) Sometimes             c) No    
1.2. Is there advice for weight control: 
a) Yes:                b) No: 
1.2.1. If yes how long this takes place: 
a) Daily                  b) Sometimes             c) No    
1.3. Is there physical activity: 
a) Yes:   b) No: 
1.3.1. If yes how long this takes place: 
a) Daily                  b) Sometimes             c) No    
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1.4.Is there  advice for foot care:   
a) Yes:    b) No 
1.4.1. If yes how long this takes place: 
a) Daily                  b) Sometimes             c) No 
1.4.2 Is there advice for eye care: 
a) No                       b) YES                         
1.4.3 Is there advice for dental care:   
a) YES                      b) NO                         
2- Pharmacological measures: 
2.1. Source of the drugs: 
a) Pharmacy:                b) Others:   
2.2. Provider of the counseling: 
A) Pharmacist:               b) Physician          C) Nurses 
2.3. Counseling about drug administration for type 2: 
a) Yes:   b) No: 
2.3. Is there patient’s awareness about hypoglycemia and how to treat it: 
a) Yes:   b) No: 
2.3.1If yes, what is the treatment: 
A) Poor knowledge about treatment  
B) Good    
C) Excellent 
2.4. Is there patient’s awareness about hyperglycemia and how to treat it: 
a) Yes:   b) No: 
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2.4.1If yes, what is the treatment: 
a) Poor knowledge about treatment    
b) Good    
c) Excellent. 
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Appendix B 
FLOW CHART SHEET 
EVERLY MONTHES 
 
Parameters First 
visit  
April May June ……. 
BMI      
FBGL (mg/dl)      
BBGL (mg/dl)      
BP (mmHg)      
Focusing on diet control      
Focusing on physical activity      
Focusing on smoker driving stop      
Regarding on foot care      
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EVERY THREE MONTHES 
 
Parameters First 
visit 
After 3 
months 
After 6 
months 
……. 
HbA1C (%)     
TG(mg/dl)     
CHOLESTEROL(mg/dl)     
HDL (mg/dl)     
LDL( mg/dl)     
After six months     
Parameters First 
visit 
After six 
months 
 
 
 
Microalbumin     
Creatnine     
     
     
Frequency of 
hyperglycemia 
    
Frequency of  
hypoglycemia 
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Side effect and adverse drug reaction evaluations: 
 
Comment:                                                  
 
 
 
 
 
 
 
 
 
Disease Drug Brand      Daily 
amount 
Side effects Drug 
interactions 
Adverse drug reactions 
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 C xidneppA
 ﺮض اﻟﺴﻜﺮيـﻣ
  
  
ﻣﺮض اﻟﺴﻜﺮي ﻳﺼﻴﺐ اﻹﻧﺴﺎن ﻧﺘﻴﺠﺔ ﻟﻨﻘﺺ ﻓﻲ هﺮﻣﻮن اﻻﻧﺴﻠﻴﻦ اﻟﻤﺴﺆول ﻋﻦ إدﺧﺎل اﻟﺠﻠﻜﻮز ﻓﻲ ﺧﻼﻳﺎ اﻟﺠﺴﻢ 
  .اﻟﺬي ﻳﺆﻣﻦ اﻟﻄﺎﻗﺔ اﻟﻼزﻣﺔ ﻟﻨﺸﺎﻃﺎت أﻋﻀﺎء اﻟﺠﺴﻢ اﻟﻤﺨﺘﻠﻔﺔ 
  .ﺧﺮ هﻨﺎﻟﻚ ﺛﻼﺛﺔ ﻣﻜﻮﻧﺎت اﺳﺎﺳﻴﺔ ﻓﻲ ﻋﻼج ﻣﺮﻳﺾ اﻟﺴﻜﺮي آﻞ ﻣﻨﻬﻤﺎ ﻻ ﻳﺆدي ﻣﻬﻤﺘﻪ ﻓﻲ اﻟﻌﻼج إﻻ ﺑﻮاﺳﻄﺔ اﻵ
  . ﻃﺒﻴﻌﺔ أو ﻧﻮع اﻷآﻞ -1
  . اﻟﻨﺸﺎط واﻟﺤﺮآﺔ اﻟﻴﻮﻣﻴﺔ ﻟﻠﻔﺮد -2
  . اﻷدوﻳﺔ -3
  : ﻃﺒﻴﻌﺔ وﻧﻮع اﻷآﻞ 
اﻟﺨﻀﺮوات ) ﻣﻦ اﻷآﻞ اﻟﻴﻮﻣﻲ أﻳﻀًﺎ ﻳﻨﺼﺢ اﻟﻤﺮﻳﺾ أن ﻳﺠﻤﻊ ﺑﻴﻦ أآﻞ % 55 -% 06 ﻳﺤﺒﺰ اآﻠﻬﺎ ﺑﻨﺴﺒﺔ :اﻟﻨﺸﻮﻳﺎت 
اﻟﻨﺸﻮﻳﺎت . ﻷﻧﻬﺎ ﺗﺴﺎﻋﺪ و ﺗﺴﺎهﻢ ﻓﻲ ﺗﻘﻠﻴﻞ ﻧﺴﺒﺔ اﻟﺠﻠﻜﻮز أو اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم ﻋﻨﺪ اﻣﺘﺼﺎﺻﻬﺎ ( اﻟﻐﻨﻴﺔ ﺑﺎﻷﻟﻴﺎف واﻟﻨﺸﻮﻳﺎت
ﻳﺤﺒﺰ اآﻞ أﻧﻮاع ﻣﺨﺘﻠﻔﺔ ﻣﻦ . ﻟﺸﻌﻴﺮ ، اﻷرز ، اﻟﺸﻮﻓﺎن ﻣﻮﺟﻮدة ﻓﻲ اﻟﻘﻤﺢ اﻷﺑﻴﺾ واﻷﺳﻤﺮ ، دﻗﻴﻖ اﻟﺬرة ، اﻟﺒﻄﺎﻃﺲ ، ا
ﻋﻨﺪ آﻞ اﻟﻮﺟﺒﺎت ﻷن آﻞ ﻣﻨﺘﺞ ﻳﻌﻄﻴﻨﺎ ﻧﺴﺐ ﻣﺨﺘﻠﻔﺔ ﻣﻦ ( اﻟﺮﻏﻴﻒ)ﻣﻨﺘﺠﺎت اﻟﺪﻗﻴﻖ ﺧﻼل اﻟﻴﻮم وﻋﺪم اﻻﻋﺘﻤﺎد ﻋﻠﻰ اﻟﻌﻴﺶ 
  .ﺳﻜﺮ اﻟﺠﻠﻜﻮز ﻓﻲ اﻟﺪم ﻟﺬﻟﻚ ﻳﺤﺒﺰ اﻟﺘﻨﻮع 
ﺑﻨﺴﺒﺔ ﻋﺎﻟﻴﺔ ﻣﻦ اﻟﺪهﻮن ﻓﻲ اﻟﺪم ، اﻟﻨﺴﺒﺔ اﻟﻤﺴﻤﻮح ﻣﻦ اﻷآﻞ اﻟﻴﻮﻣﻲ واﻟﻤﺮﺿﻰ اﻟﻤﺼﺎﺑﻴﻦ % 03 ﻧﺴﺒﺔ اﻟﺪهﻮن :اﻟﺪهﻨﻴﺎت 
واﻟﺪهﻮن اﻟﻤﻔﺮوض اﺳﺘﻌﻤﺎﻟﻬﺎ هﻲ اﻟﻐﻴﺮ ﻣﺸﺒﻌﺔ اﻟﻤﺴﺘﺨﺮﺟﺔ ﻣﻦ اﻟﻨﺒﺎﺗﺎت وهﻲ اﻷﻓﻀﻞ واﻷﺣﺴﻦ ﻣﺜًﻼ زﻳﺖ %  51ﺑﻬﺎ 
ﻣﺎدة اﻟﻜﻮﻟﻴﺴﺘﺮول اﻟﻤﻮﺟﻮدة آﺜﻴﺮًا ﻓﻲ ﺻﻔﺎر اﻟﺒﻴﺾ وﻓﻲ . ﻋﺒﺎد اﻟﺸﻤﺲ ، زﻳﺖ اﻟﺬرة ، زﻳﺖ اﻟﺰﻳﺘﻮن ، زﻳﺖ اﻟﺴﻤﺴﻢ 
 اﻟﺒﻠﺪي اﻟﻤﺴﺘﺨﺮج ﻣﻦ ﻣﻨﺘﺠﺎت اﻷﻟﺒﺎن ﻣﺜﻞ  اﻟﺴﻤﻦ ، اﻟﺰﺑﺪة ، اﻟﻘﺸﻄﺔ اﻟﻤﺴﺘﺨﺮﺟﺔ ﻣﻦ اﻟﻠﺒﻦ واﻟﺠﻠﺪ اﻟﺨﺎرﺟﻲ اﻟﺴﻤﻦ
ﻣﺎدة اﻟﻜﻮﻟﻴﺴﺘﺮول ﻓﻬﻲ ﻣﺆذﻳﺔ ﺑﺎﻟﻨﺴﺒﺔ ﻟﺨﻼﻳﺎﻧﺎ ﻓﻲ اﻟﺠﺴﻢ ﻷﻧﻬﺎ ﺗﺘﺮآﺰ ﻓﻲ اﻷوﻋﻴﺔ اﻟﺪﻣﻮﻳﺔ وﻧﺼﻴﺐ . اﻟﻤﻮﺟﻮد ﻓﻲ اﻟﻄﻴﻮر 
  . اﻹﻧﺴﺎن ﺑﺎﻟﺠﻠﻄﺎت وأﻣﺮاض اﻟﻘﻠﺐ 
واﻻﻣﺘﻨﺎع ﻋﻦ اﻟﻠﺤﻮم % 01وﻓﻲ ﺣﺎﻟﺔ ارﺗﻔﺎع اﻟﺒﻮﻟﻴﻨﺎ ﻳﺤﺒﺬ أآﻠﻬﺎ ﺑﻨﺴﺒﺔ % 02 – 01ﻜﻤﻴﺔ اﻟﻤﺴﻤﻮح ﺑﻬﺎ هﻲ  اﻟ:اﻟﺒﺮوﺗﻴﻨﺎت 
  . اﻟﺤﻤﺮاء واﻟﻜﺒﺪ واﻟﻜﻼوي ﻗﺪر اﻹﻣﻜﺎن 
  .هﻲ اﻷﻓﻀﻞ ﻟﻤﺮﺿﻰ اﻟﺴﻜﺮي ( اﻟﻌﺪس، اﻟﻔﻮل اﻟﻤﺼﺮي، اﻟﺒﺴﻠﺔ، اﻟﻜﺒﻜﺒﻴﻚ ) اﻟﺒﺮوﺗﻴﻨﺎت اﻟﻨﺒﺎﺗﻴﺔ اﻟﻤﻮﺟﻮدة ﻓﻲ اﻟﺒﻘﻮﻟﻴﺎت 
اﻟﺘﻲ ﺗﺴﺘﻌﻤﻞ ﻓﻲ اﻟﺴﻠﻄﺔ ﻣﻔﻴﺪة ﻓﻲ إﻋﻄﺎﺋﻨﺎ اﻟﻔﺎﺗﻤﻴﻨﺎت واﻋﻄﺎﺋﻨﺎ اﻟﻄﺎﻗﺔ اﻟﺘﻲ ﻧﺤﺘﺎﺟﻬﺎ ﻓﻲ أوﻗﺎت ﻋﺪم : ﻴﻌﻴﺔ اﻟﺨﻀﺮوات اﻟﻄﺒ
  .اﻷآﻞ وأﻳﻀًﺎ ﻣﺤﺎﻓﻈﺔ ﺟﺴﻤﻨﺎ ﻓﻲ ﻋﺪم اﻟﺪﺧﻮل ﻓﻲ هﺒﻮط اﻟﺴﻜﺮي ﻳﺤﺒﺬ أآﻞ ﺧﻤﺲ إﻟﻰ ﺛﻼث ﻗﻄﻊ ﻳﻮﻣﻴًﺎ 
ﻟﺬﻟﻚ ﻳﻨﺼﺢ ﺑﺎﺳﺘﻌﻤﺎل . ﻷﻧﻬﺎ ﻏﻴﺮ ﻣﻀﺮة آﺘﻠﻚ  اﻟﻤﻮﺟﻮدة ﻓﻲ اﻟﻔﻮاآﻪ اﺣﺴﻦ ﻣﻦ اﻟﺴﻜﺮ اﻻﺑﻴﺾ آﺜﻴﺮًا :اﻟﺴﻜﺮﻳﺎت اﻟﻄﺒﻴﻌﺔ 
اﻟﺴﻜﺮ اﻟﻤﺼﻨﻊ ﺧﺼﻴﺼًﺎ ﻟﻤﺮﺿﻰ اﻟﺴﻜﺮي اﻟﻤﻮﺟﻮد ﻓﻲ اﻟﺼﻴﺪﻟﻴﺎت وأﻳﻀًﺎ أآﻞ اﻟﻔﻮاآﻪ ﻣﻦ ﺧﻤﺲ إﻟﻰ ﺛﻼث ﻗﻄﻊ ﻳﻮﻣﻴًﺎ 
  . ﻣﺘﻮﺳﻄﺔ اﻟﺤﺠﻢ ﻓﻲ أوﻗﺎت ﻣﺨﺘﻠﻔﺔ ﻣﻦ اﻟﻴﻮم 
  . ﺗﻘﻠﻴﻞ أآﻞ اﻟﻤﻠﺢ ﺧﺎﺻﺔ اﻟﻤﺼﺎﺑﻴﻦ ﺑﻤﺮض اﻟﻀﻐﻂ -
ﺸﻲ ﻟﻤﺮﻳﺾ اﻟﺴﻜﺮي هﻲ ﻧﺼﻒ ﺳﺎﻋﺔ ﻳﻮﻣﻴًﺎ ﻷﻧﻬﺎ وﺟﺪت ﺗﺰﻳﺪ ﻣﻦ ﺣﺴﺎﺳﻴﺔ اﻻﻧﺴﻠﻴﻦ أي رﻳﺎﺿﺔ اﻟﻤ: اﻟﺤﺮآﺔ اﻟﻴﻮﻣﻴﺔ 
  . ﺳﺎﻋﺔ 84ﻟﻠﺨﻼﻳﺎ أو آﻞ 
ﻋﻨﺪﻣﺎ  ﺗﺒﺪأ رﻳﺎﺿﺔ اﻟﻤﺸﻲ ﻻ ﺑﺪ أن ﺗﻜﻮن ﻣﻬﻲ ﻧﻔﺴﻚ ﺑﺤﻴﺚ ﺗﻜﻮن ﺁﺧﺬ وﺟﺒﺔ ﺧﻮﻓًﺎ ﻣﻦ اﻟﺘﻌﺮض ﻟﻬﺒﻮط ﻓﻲ 
  . اﻟﺴﻜﺮي 
ﻤﺮﺟﻮة ﻣﻦ اﻟﻌﻼج ﻷن اﻟﻨﺘﻴﺠﺔ اﻟﻜﺎﻣﻠﺔ ﺑﺎﻟﻨﺴﺒﺔ ﻟﻚ  اﻟﻌﻼج اﻟﻤﻌﻄﻰ ﺑﻮاﺳﻄﺔ اﻟﻄﺒﻴﺐ هﻮ ﻻ ﻳﻌﻄﻴﻨﺎ اﻟﻨﺘﻴﺠﺔ اﻟ:اﻷدوﻳﺔ 
آﻤﺮﻳﺾ وﻟﺼﺤﺘﻚ هﻲ أﺧﺬ اﻟﻌﻼﺟﺎت ﺑﺎﻧﺘﻈﺎم ﺣﺴﺐ ﺗﻮﺟﻴﻪ اﻟﻄﺒﻴﺐ اﻟﻤﺨﺘﺺ واﻟﺼﻴﺪﻟﻲ واﻻﺑﺘﻌﺎد ﻋﻦ اﻻﻧﻔﻌﺎﻻت اﻷآﻞ 
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اﻟﺼﺤﻲ اﻟﻤﺘﻮازن ﺣﺴﺐ أرﺷﺎدات اﺧﺘﺼﺎﺻﻲ اﻟﺘﻐﺬﻳﺔ ﻣﻊ اﻻﻧﺘﻈﺎم ﻓﻲ اﻟﻮﺟﺒﺎت ﻣﻊ رﻳﺎﺿﺔ اﻟﻤﺸﻲ وﺑﺎﻟﺘﺎﻟﻲ ﺗﺬهﺐ ﻋﻨﻨﺎ 
ﻔﺎع اﻟﺴﻜﺮي ﻣﺜﻞ اﻟﺘﺒﻮل اﻟﻤﺘﻜﺮر ﺧﺎﺻﺔ ﻟﻴًﻼ ، اﻟﻌﻄﺶ ، اﻟﺠﻮع اﻟﺸﺪﻳﺪ واﻻﻟﺘﻬﺎﺑﺎت اﻟﻤﻬﺒﻠﻴﺔ اﻟﻤﺘﻜﺮرة اﻟﻨﺴﺎﺋﻴﺔ أﻋﺮاض ارﺗ
 041 ﻋﻨﺪ اﻟﺼﻴﺎم وﺑﻌﺪ اﻷآﻞ ﺑﺴﺎﻋﺘﻴﻦ أﻗﻞ ﻣﻦ دل/ﻣﻠﺠﻢ ( 011 – 001)ﻟﺬﻟﻚ ﻻﺑﺪ ﻣﻦ اﻟﺤﻔﺎظ ﻋﻠﻰ ﻣﺴﺘﻮى ﺳﻜـﺮﻧﺎ ﺑﻴﻦ 
   .دل/ﻣﻠﺞ 
  .ع اﻹرﺷﺎدات اﻟﻤﻘﺪﻣﺔ ﻣﻦ ﻣﺘﺨﺼﺺ ﻓﻲ اﻟﻌﻨﺎﻳﺔ ﺑﺎﻷﻗﺪام  اﻻهﺘﻤﺎم واﻟﻌﻨﺎﻳﺔ ﺑﺎﻟﻘﺪﻣﻴﻦ ﺑﻮاﺳﻄﺔ اﺗﺒﺎ-
 اﻻهﺘﻤﺎم ﺑﺰﻳﺎرة ﻃﺒﻴﺐ اﻟﻌﻴﻮن ﻣﻦ ﺗﺎرﻳﺦ ﻣﻌﺮﻓﺔ اﻟﻤﺮض ﻟﺘﻄﻠﻊ ﻋﻠﻰ ﻣﺮاﺣﻞ اﻟﻤﺮض ﻋﻠﻰ ﻋﻴﻨﻴﻚ ﺣﺘﻰ ﻻ ﺗﺼﺎب ﺑﺎﻟﻌﻤﻰ -
  .ﻓﻲ ﻣﺮاﺣﻞ اﻟﻌﻤﺮ اﻟﻤﺘﻘﺪﻣﺔ 
ض ﻋﻠﻰ اﺳﻨﺎﻧﻚ ﺣﺘﻰ ﻻ ﺗﻔﻘﺪ  اﻻهﺘﻤﺎم ﺑﺰﻳﺎرة ﻃﺒﻴﺐ اﻷﺳﻨﺎن ﻣﻦ ﺗﺎرﻳﺦ ﻣﻌﺮﻓﺔ اﻟﻤﺮض ﻟﺘﻄﻠﻊ ﻋﻠﻰ ﻣﺮاﺣﻞ ﺗﻄﻮر اﻟﻤﺮ-
  .اﺳﻨﺎﻧﻚ ﻓﻲ ﺳﻦ ﻣﺒﻜﺮة ﻣﻦ اﻟﻌﻤﺮ 
 % 05 ﻣﻌﺮﻓﺔ أﻋﺮاض هﺒﻮط اﻟﺴﻜﺮي ﺣﺘﻰ ﻧﺄﺧﺬ ﺣﺬرﻧﺎ ﻓﻲ اﻟﻤﺴﺘﻘﺒﻞ اﻟﻘﺮﻳﺐ ﻓﻤﺜًﻼ إذا ﺳﻜﺮ اﻟﺪم هﺒﻂ إﻟﻰ ﻣﻌﺪل أﻗﻞ ﻣﻦ -
ﻷوﻟﻴﺔ إﻟﻰ  ﻓﺈﻧﻨﺎ ﻧﺤﺲ ﺑﺮﺟﻔﺔ ﺛﻢ اﻟﻌﺮق اﻟﺸﺪﻳﺪ ، ﺿﺮﺑﺎت ﻓﻲ اﻟﻘﻠﺐ ، زﻏﻠﻠﺔ ﻓﻲ اﻟﻌﻴﻮن ، ﻋﺪم ﺗﺮآﻴﺰ اﻷﻋﺮاض ادل/ﻣﻠﺞ 
) ا ﻣﻬﻲ ﻧﻔﺴﻚ إﻟﻰ اﻟﻤﺸﻮار 1اﻷﻋﺮاض اﻟﺘﻲ ﺗﺆدي إﻟﻰ اﻟﺪﺧﻮل ﻓﻲ اﻟﻐﻴﺒﻮﺑﺔ ﻟﺬﻟﻚ ﻻﺑﺪ  ﻣﻦ أﺧﺬ اﻟﻮﺟﺒﺎت ﻓﻲ ﻣﻮاﻋﻴﺪهﺎ ، إ
وأﻳﻀًﺎ . ﻻ ﺑﺪ أن ﺗﺄﺧﺬ وﺟﺒﺔ ﺧﻮﻓًﺎ ﻣﻦ اﻟﺪﺧﻮل ﻓﻲ هﺒﻮط اﻟﺴﻜﺮ وأﻧﺖ ﺟﻮﻋﺎن (  دﻗﻴﻘﺔ أو أآﺜﺮ 02ﻣﺸﻴًﺎ ﺑﺎﻷرﺟﻞ ﻓﻲ ﺣﺪود 
ﻮع ﻻ ﺑﺪ ﻣﻦ أﺧﺬ ﻓﺎآﻬﺔ ﻣﺘﻮﺳﻄﺔ اﻟﺤﺠﻢ أو أﺧﺬ ﻓﻮل ﺳﻮداﻧﻲ ﻏﻴﺮ ﻣﻤﻠﺢ أو ﻣﻜﺴﺮات هﺬﻩ ﺑﻴﻦ اﻟﻮﺟﺒﺎت إذا أﺣﺴﺴﻨﺎ ﺑﺎﻟﺠ
  . اﻟﻄﺮﻳﻘﺔ ﻻ ﺗﺪﺧﻠﻨﺎ ﻓﻲ هﺒﻮط اﻟﺴﻜﺮي وﺗﺤﺎﻓﻆ ﻋﻠﻰ ﻣﻌﺪل اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم 
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Appendix D 
 
 
